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Abstract
Extracellular deposition of beta-Amyloid (Aβ) is an early event in Alzheimer’s disease
development. However, it is not known how Aβ is secreted. Lysosomes readily undergo
calcium-dependent exocytosis, a process that relies on small GTPase Rab27b. In addition,
lysosomal enzymes have been found within extracellular amyloid plaques. We
hypothesized that lysosomes mediate Rab27b-dependent exocytosis of Aβ. Neuro-2a cells
were transfected with wild-type or mutant Rab27b constructs and/or a lysosomal marker.
Cells were incubated with Aβ monomers and imaged using a confocal microscope before
and after stimulation of calcium-dependent exocytosis. We observed a significant
decrease in lysosome and Aβ co-localization post-treatment in comparison to pretreatment in control samples. We also observed a significant increase in lysosome and Aβ
co-localization post-treatment in Rab27b dominant-negative mutants in comparison to
control. These results demonstrate that lysosomes can mediate Rab27b-dependent
exocytosis of Aβ, thus elucidating a mechanism by which Aβ could be secreted in
Alzheimer’s disease.

Keywords
Alzheimer’s disease (AD), beta-Amyloid (Aβ), Aβ42, Aβ40, small GTPase Rab27b,
lysosomes, calcium-dependent (regulated) exocytosis, secretion

Summary for Lay Audience
Alzheimer’s disease is the leading form of dementia, in which patients experience
progressive cognitive decline. In Alzheimer’s disease, a toxic protein named beta-Amyloid
is produced within and subsequently released from cells, forming deposits within the brain.
It has been suggested that the production of beta-Amyloid triggers a cascade of events that
results in the development of Alzheimer’s disease. However, it is not known how betaAmyloid is released from cells.
Previous research has implicated the involvement of lysosomes in Alzheimer’s disease
progression. Lysosomes are classically viewed as waste disposal compartments within the
cell. Recent studies have shown that lysosomes are also capable of discharging their
contents to the outside of the cell. This process has been suggested to be dependent on
protein Rab27b, which brings lysosomes closer to the membrane of a cell. When lysosomes
are near the cell’s membrane, an increase in calcium within the cell enables lysosomes to
release their contents. In this study, it was hypothesized that beta-Amyloid is discharged
from lysosomes with the assistance of protein Rab27b.
To investigate this hypothesis, cells were manipulated to express inactive, active, or
overactive protein Rab27b and/or a lysosome indicator. Cells were also loaded with betaAmyloid. In this manner, lysosomes and beta-Amyloid present within cells that were or
were not manipulated to express inactive, active, or overactive Rab27b were able to be
observed under a microscope. Cells were then stimulated to discharge the contents of their
lysosomes by increasing the amount of calcium within these cells. Cells were again
observed under a microscope. Microscope images taken before and after stimulation of
discharge were compared to determine differences in beta-Amyloid release. It was
observed that lysosomes can release beta-Amyloid from cells with the assistance of protein
Rab27b.
By the year 2050, it is predicted that more than 130 million new cases of Alzheimer’s
disease will arise worldwide. Understanding how beta-Amyloid is released from cells
would facilitate the development of targeted treatments for Alzheimer’s disease, which are
essential to preventing future disease progression.
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Chapter 1

1

Introduction

Extracellular beta-Amyloid (Aβ) deposition is an early event in the development of
Alzheimer’s disease (AD) [1]; however, it is not known how Aβ is secreted. This study was
therefore conducted to elucidate the means of Aβ secretion in the context of AD. Previous
research has suggested that lysosomes may be vital to calcium-dependent exocytosis of Aβ
[2]–[5]. Calcium-dependent exocytosis involves the coordinated activity of many different
proteins, such as small GTPase Rab27b [6]–[9].
The related topics of lysosomes, exocytosis, small GTPase Rab27b, and AD were reviewed
in-depth in Chapter 1 to provide the reader with a foundation for this study. To determine
whether lysosomes mediate calcium-dependent exocytosis of Aβ and further, to determine
whether this exocytotic process is dependent on Rab27b, we conducted a group of
experiments described in detail in Chapters 2 and 3. These experiments included
transfecting Neuro-2a (N2A) cells with fluorescent Rab27b mutant or wild-type (WT)
constructs and/or a fluorescent lysosomal marker, incubating the cells with dye-labeled Aβ
monomers, imaging the cells under confocal microscopy before and after stimulation of
calcium-dependent exocytosis with ionomycin treatment, and conducting co-localization
analyses of the images obtained. Results of this study were presented in Chapter 3. Briefly,
a significant decrease in lysosome and Aβ co-localization post-treatment in comparison to
pre-treatment in control samples was observed, indicative of lysosomal-mediated secretion
of Aβ. A significant reduction of lysosomal-mediated secretion of Aβ in Rab27b dominantnegative mutants in comparison to control samples was also observed. These results were
discussed in Chapter 4, in the context of the literature reviews provided in Chapter 1.
Overall, the results of this study demonstrate that Aβ secretion is mediated by lysosomes
in a Rab27b-dependent manner, thus elucidating a mechanism by which Aβ could be
secreted in AD.
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1.1 Lysosomes
1.1.1 Overview
Lysosomes are membrane-bound, acidic organelles that are found in eukaryotic cells in
varying amounts. Each conventional lysosome contains over 50 different types of acid
hydrolases, or enzymes that function optimally in acidic environments [10]. The restricted
pH optimum of acid hydrolases allows conventional lysosomes to degrade a vast array of
material that is trafficked to them, while also offering protection for the rest of the cell.
Specifically, if the lysosomal membrane were to become compromised and acid hydrolases
were to be released to the cytosol, material in the cytosol would not be degraded. This is
due to activity of acid hydrolases within the acidic environment of the lysosome (pH of 4.5
to 5) and inactivity of acid hydrolases within the neutral environment of the cytosol (pH of
approximately 7.2) [10], [11]. To maintain the lysosomal lumen at a low pH, the lysosome
must actively transport protons (H+ ions) from the cytosol to the lysosomal lumen via a
proton pump known as vacuolar ATPase [12]. In order to offset a large positive
electrochemical gradient, transport of H+ ions from the lysosomal lumen to the cytosol and
transport of chloride ions (Cl-) from the cytosol to the lysosomal lumen occurs
simultaneously, primarily via Cl- / H+ antiporter CIC-7 [13], [14].
Material that can be degraded by lysosomal acid hydrolases includes intracellular and
extracellular proteins, lipids, carbohydrates, and nucleic acids that are aberrant or otherwise
damaged [10], [11]. Lysosomal-mediated turnover of intracellular material, such as
damaged organelles, primarily occurs through a process termed macroautophagy [15].
Macroautophagy is dependent on the formation of a vesicle, a continuous lipid bilayer(s)
that encloses either extracellular fluid or cytoplasm and may contain soluble and/or
membrane-bound material [16]. The specialized double membrane-bound intracellular
vesicle formed during macroautophagy is called an autophagosome. An autophagosome
can eventually fuse with a lysosome to form an autolysosome, which exposes intraluminal
material to lysosomal acid hydrolases that catalyze their digestion [15].
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Extracellular material destined for degradation by the lysosome must first be internalized
by the cell in a process termed endocytosis [10], [11]. Two main types of endocytic
mechanisms that direct extracellular material to the lysosome for degradation are
phagocytosis and pinocytosis [17], [18]. Phagocytosis refers to the engulfment of
extracellular material by the plasma membrane and subsequent budding of this membrane
to form a phagosome. Similar to the mechanism of macroautophagy, a phagosome is an
intracellular vesicle that fuses with a lysosome to form a phagolysosome, ultimately
enabling digestion of phagocytosed material via exposure to lysosomal acid hydrolases.
Material that is endocytosed in this manner can include large extracellular pathogens (equal
to or greater than 0.5 µm) and dead cell debris [19]. Pinocytosis refers to invagination of
the cell’s membrane to form a non-specific fluid and material-filled intracellular vesicle.
This vesicle can then fuse with a lysosome for degradation of its contents [17].
1.1.2 Secretory Lysosomes and Lysosome-Related Organelles
Apart from the ability to degrade material via resident acid hydrolases, a subset of
lysosomes present within most cell types additionally possess the ability to store and release
material to the extracellular space in a process termed calcium-dependent exocytosis
(calcium-dependent exocytosis is described in detail in Section 1.2.1). These lysosomes are
referred to as secretory lysosomes [20], [21]. Despite the additional ability of secretory
lysosomes to undergo exocytosis, there are no differences in morphology of secretory
lysosomes when compared to conventional lysosomes [20]. In functionality, secretory
lysosomes

are

related

to

secretory

vesicles,

early

endosomes,

and

late

endosomes/multivesicular bodies (MVBs) [20], [21].
Secretory lysosomes that are specific to the cell type they are found in are termed lysosomerelated organelles (LROs). LROs are specialized compartments that share many properties
with secretory lysosomes, including the ability to undergo calcium-dependent exocytosis.
However, as these compartments are cell-specific, they release cell-specific proteins to the
extracellular space [20], [22]. Examples of LROs include lytic granules of cytotoxic T cells,
which secrete cytolytic proteins (immune cell effectors), and melanosomes of melanocytes,
which secrete melanin (a pigment) [20]–[22]. Lytic granules and melanosomes are
discussed in greater detail in Section 1.1.4.
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Many studies use Total Internal Reflection Fluorescence Microscopy (TIR-FM) to observe
lysosomes undergoing calcium-dependent exocytosis in vitro [5], [7], [23]. In TIR-FM, a
laser is reflected off the surface of a confocal plate or coverslip at a critical reflection angle,
such that only a small amount of energy (termed an evanescent wave) can penetrate a cell.
This process excites fluorophores present within 70-250 nm of the cell’s surface. As such,
background signal that may be captured under epifluorescence microscopy is omitted in
TIR-FM. Moreover, time-lapse videos can be captured within milliseconds between frames
under TIR-FM. TIR-FM is therefore a technique that enables researchers to observe
processes occurring adjacent to a live cell’s plasma membrane in detail and in real-time
[24]. However, as only a small amount of energy can penetrate a cell under TIR-FM, a
major limitation of this microscopy technique is the need for relatively high laser powers
for efficient excitation of fluorophores. The use of high laser powers can in turn result in
rapid photobleaching of these fluorophores. Confocal microscopy and live-cell widefield
microscopy can be used as alternative techniques to TIR-FM when observing indirect or
direct lysosomal-mediated secretion, respectively. With confocal and widefield
microscopy, images can be taken at resolutions (confocal) and speeds (widefield)
comparable to TIR-FM [25].
Numerous luminal and membrane lysosomal markers have been developed to observe
lysosomal-mediated secretion under microscopy. Many lysosomal markers used in livecell imaging make use of the organelle’s acidic lumen [5], [23], [26]. For example, our
laboratory has previously utilized construct mApple-LAMP1-pHluorin (Addgene plasmid
#54918). mApple fluorescent protein labels the cytosolic end of the transmembrane (TM)
glycoprotein Lysosomal-Associated Membrane Protein 1 (LAMP1) red, and ecliptic
pHluorin labels the luminal end of LAMP1 green. Ecliptic pHluorin is a pH-sensitive Green
Fluorescent Protein (GFP) that increases in fluorescence intensity when it is exposed to a
less acidic environment (higher pH) [27]. As lysosomes are acidic organelles and the
extracellular environment more basic in comparison, gradual increases in fluorescence
intensity of ecliptic pHluorin-labeled lysosomes previously enabled our laboratory to
visualize lysosomal-mediated secretion of Aβ in real-time using live-cell microscopy
techniques such as TIR-FM and widefield.
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1.1.3 Sorting of Normal Material to the Lysosome
Lysosomal sorting of normal material, such as resident membrane-bound glycoproteins and
resident soluble acid hydrolases, can occur through indirect and direct pathways [21], [28].
The indirect sorting pathway entails trafficking of a newly-synthesized membrane-bound
protein from the trans-Golgi network (TGN) to the plasma membrane via constitutive
exocytosis (described in Section 1.2), internalization of the membrane-bound protein from
the plasma membrane via receptor-mediated (clathrin-mediated) endocytosis, and
intracellular trafficking of this protein to the lysosome via the endocytic pathway. Many
resident TM glycoproteins, including LAMPs, are sorted to the lysosome in this manner
[28], [29]. Clathrin-mediated endocytosis refers to invagination of the cell’s membrane and
associated proteins to form endocytic vesicles lined by an outer clathrin protein coat. Cell
surface TM proteins that are destined for transport to the lysosome contain tyrosine(YXXØ) or dileucine- ([DE]XXXL[LI]) based motifs on their cytoplasmic domains [30].
During clathrin-mediated endocytosis, these motifs enable clathrin adaptor protein (AP)
complex AP-2 to bind and subsequently recruit clathrin proteins for the construction of a
lattice that aids in the assembly of a clathrin-coated vesicle upon invagination of the plasma
membrane [18], [31]. Following the endocytic pathway, clathrin-coated vesicles then fuse
with an early endosome for transfer of cargo. Early endosomes are membrane-bound
organelles that function as sorting centers for internalized material [32]. The maturation of
an early endosome into a late endosome/MVB is necessary for material that is destined for
transport to the lysosome. This maturation process involves acidification of the lumen, from
a pH of approximately 6.5 to a pH of approximately 5.5. Maturation also involves the
generation of intraluminal vesicles (ILVs) [33].
The generation of ILVs within the early endosome is dependent on endosomal sorting
complexes required for transport (ESCRT). ESCRT promotes inward budding and scission
of the limiting membrane of the early endosome to form these ILVs. ESCRT is comprised
of cytosolic protein complexes ESCRT-0, ESCRT-I, ESCRT-II, and ESCRT-III that are
each capable of recognizing different components of the early endosome and/or its
associated cargo [34], [35]. For example, early endosomes that carry material destined for
transport to the lysosome contain discontinuous and bi-layered flat clathrin coats that lack
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APs and are thus morphologically distinct from the clathrin coats of endocytic vesicles
[36]. Recruitment of ESCRT to an early endosome carrying such material is dependent on
the recognition of its flat clathrin coat via ESCRT-0 protein, hepatocyte growth factorregulated tyrosine kinase substrate (Hrs). This interaction is mediated through a clathrin
box motif present within the C-terminal domain of Hrs [32].
Upon maturation, the late endosome/MVB can fuse with a lysosome for transfer of its ILVs
or associated cargo [33]. ILV membranes contain bis (monoacylglycero) phosphate /
lysobisphosphatidic acid (BMP/LBPA), a negatively-charged phospholipid that can enable
back-fusion of the ILV membrane with the limiting membrane of the late endosome/MVB,
for release of membrane-bound cargo to the late endosome/MVB membrane [37].
BMP/LBPA is also capable of recruiting positively-charged lipid hydrolases for breakdown
of the ILV membrane, for release of soluble cargo to the late endosome/MVB lumen [33].
The direct sorting pathway to the lysosome involves trafficking of a soluble or membranebound protein from the TGN to a late endosome/MVB. This late endosome/MVB can then
fuse with the lysosome for transport of its cargo [28], [29]. The majority of newlysynthesized lysosomal acid hydrolases are sorted in this manner. These acid hydrolases
must first be post-translationally modified with a unique marker that signals the proteins
for direct sorting to the lysosome. Modification involves the addition of mannose-6phosphate (M6P) groups to oligosaccharides of acid hydrolases within the lumen of the cisGolgi network (CGN) [38]. This post-translational modification is catalyzed by the
enzymes N-acetylglucosamine-1-phosphotransferase (GlcNAc-1-phosphotransferase) and
GlcNAc-1-phosphodiester α-N-acetylglucosaminidase (also known as “uncovering
enzyme” or UCE) [29]. Once modified, M6P-tagged proteins are transported to the lumen
of the TGN, where they recognize and attach to the ligand-binding sites of TM M6P
receptors [39]. On the cytosolic side of the TGN, these same receptors bind the clathrin AP
complex AP-1. AP-1 then recruits clathrin proteins to form clathrin-coated vesicles that
bud from the TGN for transport to late endosomes/MVBs [30], [31]. The specific binding
of M6P-tagged proteins to M6P receptors occurs within the TGN at a pH of approximately
6.5. Release of M6P-tagged proteins from M6P receptors occurs during fusion of clathrincoated vesicles and late endosomes/MVBs, upon exposure to a more acidic MVB luminal
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pH of approximately 5.5 [11]. Fusion of late endosomes/MVBs with lysosomes enables
sorting of soluble acid hydrolases to the lysosome [29].
1.1.4 Lysosomal Storage Diseases
When a lysosome is unable to digest a certain kind of material, this material can accumulate
within the lysosome and produce symptoms that are characteristic of one of 50 lysosomal
storage diseases (LSDs) in humans. In common LSDs, a gene encoding a lysosomal
enzyme is mutated such that the enzyme is deficient in activity or amount, or cannot be
produced altogether [40]. For example, the most common type of LSD is Gaucher’s disease
(GD) [41]. GD can be caused by autosomal recessive mutations in the GBA gene, in turn
resulting in reduced expression of the lysosomal acid hydrolase β-glucocerebrosidase. This
enzyme hydrolyzes a glycosidic bond within the cell membrane lipid glucocerebroside
[41], [42]. When cells undergo cell death, macrophages and other phagocytic cells can
phagocytose these dead cell components (including glucocerebroside of the plasma
membrane) and subsequently traffic them to lysosomes for degradation [17], [19].
Deficiency of β-glucocerebrosidase therefore results in accumulation of glucocerebroside,
primarily within lysosomes of macrophages throughout the body [43], [44]. This results in
symptoms ranging from anemia to hepatosplenomegaly (enlargement of the liver and
spleen) in non-neuronopathic forms of GD (Type 1). In neuronopathic forms of GD (Type
2 and Type 3), cognitive impairment and seizures are also observed [45].
LSDs can also occur when multiple lysosomal enzymes cannot be incorporated into
lysosomes, such that non-specific material accumulates within lysosomes. Inclusion-cell
disease (also known as I-cell disease or Mucolipidosis II) is caused by an autosomal
recessive mutation in the GNPTA gene. This mutation reduces GlcNAc-1phosphotransferase expression, which results in a decreased amount of newly-synthesized
acid hydrolases that are post-translationally modified with M6P groups [46]. As these acid
hydrolases do not contain a signal sequence, they cannot be sorted to the lysosome and are
instead secreted to the extracellular space via constitutive exocytosis [47]. Due to missorting of multiple types of acid hydrolases, certain material in the lysosome cannot be
degraded. This results in non-specific inclusions within the lysosomal lumen. Symptoms
of I-cell disease include severe developmental and growth delays [46].
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In addition, certain types of LSDs can arise when genes encoding proteins that are involved
in vesicle trafficking or vesicle docking are mutated, such that the vesicle cannot undergo
normal exocytosis. For example, Griscelli syndrome (GS) is an autosomal recessive
disorder that affects the secretion of melanosomes or their contents [48]–[50]. The
melanosome is a type of LRO found within melanocytes and is required for transfer of
melanin to keratinocytes of the skin. The transfer of variable types and amounts of melanin
results in differences in skin colour [51]. Although there have been various theories
regarding the mechanism of melanin transfer, all involve secretion of the melanosome or
its contents [52]. In melanocytes, transport of perinuclear melanosomes along microtubules
and actin filaments, and docking of melanosomes to the plasma membrane [53], is
dependent on a complex comprised of three proteins: myosin Va, Rab27a, and
melanophilin (also known as Slac2-a) [48]–[50]. GS is clinically divided into three different
types of syndromes depending on the protein that is affected, with all three types of GSs
resulting in hypopigmentation of the hair and skin due to reduction in secretion and
subsequent melanin transfer [22]. However, proteins such as Rab27a are normally
expressed within several different cell types, including cytotoxic T cells. Lack of RAB27A
expression within cytotoxic T cells of GS Type 2 patients thus results in additional
immunodeficiency, due to a decrease in exocytosis of lytic granules and consequent
reductions in extracellular cytolytic proteins, such as granzymes and perforins [50].
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1.2 Exocytosis
Exocytosis can be defined as the release of intraluminal material to the plasma membrane
or extracellular space. All eukaryotic cells can undergo constitutive exocytosis (also known
as non-regulated, non-calcium-dependent, or default exocytosis), wherein material is
secreted without an initial signal or stimulus. Constitutive exocytosis occurs when proteins
that have been newly-synthesized in the endoplasmic reticulum (ER) are not posttranslationally modified in the TGN to contain a translocation sequence that would
otherwise direct their transport to another subcellular location. These proteins are packaged
into secretory vesicles within the TGN for direct transport to the plasma membrane.
Calcium-dependent exocytosis (also known as regulated exocytosis) can only occur in a
portion of eukaryotic cells and is contingent on an initial signal or stimulus for secretion of
material. Types of vesicles that can undergo calcium-dependent exocytosis as described
below include some secretory vesicles, late endosomes/MVBs, secretory lysosomes, and
LROs [20], [21].
1.2.1 Calcium-Dependent Exocytosis in the Context of Neuronal Lysosomes
Calcium-dependent exocytosis in neurons transpires in four or five steps: 1) vesicle
trafficking, 2) vesicle tethering, 3) vesicle docking, 4) vesicle priming, and 5) vesicle fusion
[20], [21]. Vesicle trafficking involves the anterograde transport of vesicles containing
newly-synthesized proteins (from the TGN toward the plasma membrane), along
microtubules, with the aid of motor protein kinesin-1 [54], [55]. Once the vesicle is adjacent
to the plasma membrane, it detaches from kinesin-1 and travels the rest of the distance
toward the plasma membrane through a region of filamentous actin, primarily with the aid
of motor protein myosin homologue non-muscle myosin heavy chain IIA (NMHC-IIA)
[56]. Rather than immediately undergoing exocytosis, vesicles generated in the TGN can
instead be stored distal to the plasma membrane in “recycling” or “reserve” pools. Upon
initiation of calcium-dependent exocytosis, these vesicles can undergo anterograde vesicle
trafficking (from areas distal, to areas proximal to the plasma membrane). Recycling pools
of vesicles refer to vesicles that can be trafficked to the membrane under physiological
stimulatory conditions. Reserve pools of vesicles refer to vesicles that can only be
trafficked to the membrane when the cell is exposed to excessive stimulation. Readily
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releasable pools of vesicles are stored proximal to the plasma membrane after generation
in the TGN [5], [57]. These vesicles have therefore undergone trafficking prior to initiation
of calcium-dependent exocytosis. Regardless of whether a vesicle must first be trafficked
or is already proximal in location to the plasma membrane, the next step of calciumdependent exocytosis involves tethering of this vesicle to the plasma membrane. Vesicle
tethering occurs via formation of an octameric protein tethering complex named exocyst
[58]. Mammalian subunits EXOC2 to EXOC6 and EXOC8 are localized to the vesicle
membrane, and mammalian subunits EXOC1 and EXOC7 are localized to the plasma
membrane [59]. The interaction between exocyst subunits localized to vesicle and plasma
membranes results in formation of the aforementioned exocyst complex [58]. Vesicle
docking at the plasma membrane requires further interaction of exocyst subunits with active
Rab GTPases localized to the vesicle membrane [60]. Docking of lysosomes and LROs,
for example, is dependent on an interaction between EXOC6 (SEC15 in Saccharomyces
cerevisiae) and active Rab27 [61]. The interaction between active Rab GTPases and
exocyst subunits recruits Rab effector proteins, such as the Rab27 effector Munc13-4 [7],
[9]. Previous studies have suggested that the Rab27-Munc13-4 complex of lysosomes
serves as a “nucleation point” or “coincidence detection unit” for self-assembly or chance
interaction between soluble N-ethylmaleimide-sensitive factor attachment receptor
(SNARE) proteins [7]. SNARE proteins are categorized according to whether they are
localized to the vesicle membrane (v-SNAREs) or target (plasma) membrane (t-SNAREs)
[62]. Vesicle priming is dependent on interactions between v- and t-SNAREs for the
formation of a highly stable ternary SNARE complex. This ternary complex is comprised
of v-SNARE Vesicle-Associated Membrane Protein (VAMP; also known as
Synaptobrevin), t-SNARE Syntaxin, and t-SNARE soluble N-ethylmaleimide-sensitive
factor attachment protein (SNAP) isoforms [63]. An essential step preceding ternary bundle
formation involves the stabilization of Syntaxin isoforms in closed conformations by
Munc18 regulatory proteins [64]. In relation to lysosome- and LRO-mediated exocytosis,
Munc18-2 stabilizes Syntaxin-11 in its closed conformation [65]. Dissociation of Munc182 enables Syntaxin-11 to convert to its open conformation, which may allow Syntaxin-11
to interact with VAMP isoforms (such as VAMP-2) and SNAP isoforms (such as SNAP23) via SNARE motifs to form a ternary bundle [66], [67]. It has previously been suggested
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that regulation by Munc18 is an essential intermediate step required for proper timing of
ternary complex formation [64]. Another regulatory protein named Complexin (also known
as Synaphin) can stabilize the bundle upon its formation to prime the vesicle for fusion with
the plasma membrane [68]. Vesicle fusion with the plasma membrane is dependent on an
influx of calcium ions (Ca2+) from voltage-gated calcium channels that are present near the
primed vesicle [69]. This influx of Ca2+ also enables Ca2+ to bind to ER ryanodine receptors
(RyRs) and inositol 1,4,5-trisphosphate receptors (IP3Rs) to allow calcium-induced
calcium release (CICR) from ER stores [70]–[72]. An increase in intracellular Ca2+
concentration is required for Ca2+ to bind to C2 domains of a Synaptotagmin calcium
sensor, such as Synaptotagmin-VII of lysosomes [66], [73], and for subsequent detachment
of Complexin from the ternary bundle [68] (Figure 1). Once Complexin has disassociated,
the hydrophobic lipid bilayers of the vesicle membrane and the plasma membrane can fuse
via kiss-and-run (partial) or complete fusion. In kiss-and-run fusion, vesicles transiently
fuse with the plasma membrane such that soluble cargo is released to the extracellular
space, and the vesicle membrane remains separate from the plasma membrane. This method
of fusion allows vesicles to be recycled to the TGN. In complete fusion, vesicles
permanently fuse with the plasma membrane such that soluble cargo is released to the
extracellular space and membrane-bound cargo is secreted into the plasma membrane. This
method of fusion involves the diffusion of the vesicle membrane into the plasma
membrane, where it then becomes a permanent part of the plasma membrane [74], [75].
The mechanism that regulates kiss-and-run versus complete vesicle fusion is presently
unclear.
Calcium-dependent exocytosis can be stimulated in vitro by ionomycin. Ionomycin is a
biological carrier ionophore produced by the bacterium Streptomyces conglobatus. It
functions to transport extracellular Ca2+ to the inside of a cell and is therefore considered a
calcium ionophore. As a lipid molecule, it is hydrophobic and can bind to the plasma
membrane of a cell. Ionomycin can then bind Ca2+ to shield its positive charge from the
hydrophobic membrane, thus allowing the ion to pass across the membrane [76].
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Figure 1 – Lysosomal-mediated calcium-dependent exocytosis
Lysosomal-mediated calcium-dependent exocytosis entails a series of steps. The first step
is tethering, which involves the formation of an octameric protein tethering complex termed
exocyst. Exocyst subunits recruit and interact with active small GTPase proteins, such as
Rab27. Interaction with Rab27 in particular recruits effector protein Munc13-4, which
docks the lysosome at the plasma membrane. The Rab27-Munc13-4 complex serves as a
nucleation point for self-assembly of SNARE proteins into a ternary complex, comprised
of VAMP, Syntaxin, and SNAP protein isoforms. The formation of this ternary complex
primes the lysosome at the plasma membrane. Upon an influx of calcium ions via voltagegated calcium channels, intracellular calcium concentration increases and SynaptotagminVII protein enables fusion of the lysosome with the plasma membrane.
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1.3 Small GTPase Rab27b
1.3.1 Small GTPases: An Overview
Small GTPases are guanosine nucleotide-bound proteins that are important for a wide
variety of intracellular signalling processes. There are over 150 different types of small
GTPases that have been discovered to date; among the first to be discovered were members
of the Ras family of small GTPases. Prior to establishing their role in normal subcellular
signal transduction, Ras GTPases were considered oncoproteins due to the detection of
oncogenic mutations in genes encoding these Ras GTPases. Today, all small GTPases are
considered part of the Ras superfamily of small GTPases. The Ras GTPase superfamily
consists of at least five different families: 1) Ras, 2) Rho, 3) Rab, 4) Arf, and 5) Ran [78].
Small GTPases that belong to each of these families share common genetic sequences and
physical structures. These families can be further divided into subfamilies based on their
hypervariable C-terminal domains, which have been shown to play a role in subcellular
localization of the small GTPase and may alter the effector protein(s) that is targeted [79],
[80].
Small GTPases exist in active forms bound to guanosine triphosphate (GTP) and inactive
forms bound to guanosine diphosphate (GDP). When a small GTPase is bound to GDP, a
guanine exchange factor (GEF) can augment the intrinsic conversion from an inactive
GDP-bound form, to an active GTP-bound form. Specifically, a GEF can modify the
nucleotide-binding site of the small GTPase such that the affinity for GDP is reduced and
GDP is released to the cytoplasm [81]. As the cytoplasmic concentration of GTP is ten
times greater than that of GDP, the dissociation of GDP enables GTP to bind in its place
[82]. A small GTPase bound to GTP can then interact with an effector protein, and enable
downstream cell signaling processes to occur. To terminate cell signaling, GTP bound to
the small GTPase must undergo hydrolysis. Although small GTPases possess the ability to
catalyze their own GTP hydrolysis at a slow rate, this intrinsic process can be enhanced by
a GTPase-activating protein (GAP) (Figure 2). GTP hydrolysis will result in an inactive
GDP-bound small GTPase upon release of the γ (third) phosphate of GTP to the cytoplasm
[81].
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This study focuses on the Rab family of small GTPases, which can be divided into 10
subfamilies: Rab1, Rab3, Rab4, Rab5, Rab6, Rab8, Rab11, Rab22, Rab27, and Rab40 [83].
Post-translational modifications of all Rab GTPases include prenylation, or the addition of
hydrophobic groups to certain residues. These hydrophobic groups act as lipid anchors to
attach Rab GTPases to the cytosolic face of specific compartment membranes [84]. For
example, the post-translational addition of two geranylgeranyl groups to one or two
cysteine residues at the C-terminal domain of Rab27 enables active Rab27 to attach to the
membranes of lysosomes and LROs during exocytosis [85].
The attachment of prenylated Rab GTPases to compartment membranes is regulated by
GDP dissociation inhibitors (GDIs) and GDI displacement factors (GDFs) [86], [87]. At a
cell’s steady state, prenylated and inactive (GDP-bound) Rab is sequestered in the cytosol
by Rab-GDI. For sequestration to occur, Rab-GDI must first shield the hydrophobic groups
of Rab from the aqueous cytosolic environment [88]. Rab-GDI can then inhibit the
activation of Rab by stabilizing Rab in its inactive conformation [88], [89]. During
stimulation of the cell, Rab-GDI can deliver the inactive and prenylated Rab to its specific
subcellular location, where it can interact with a GDF [90]. Here, GDF can release the Rab
GTPase from sequestration by Rab-GDI. GDP is then free to dissociate from the Rab
GTPase, and Rab can re-activate upon binding GTP [86]. GDF has also been shown to be
responsible for the initial recruitment of the Rab-GDI-Rab GTPase complex to its specific
subcellular location [89].
1.3.2 Small GTPase Rab27b
The Rab27 subfamily in particular is essential for lysosome and LRO trafficking and
docking during exocytosis. Isoforms Rab27a and Rab27b have been observed to act
separately, cooperatively, redundantly, or sequentially, depending on the cell type and
secretory pathway in question [9]. For example, secretion of the melanosome or its contents
is dependent on the sequential action of isoform Rab27a. According to this sequential
model, Rab27a initially targets and recruits effector protein melanophilin (Slac2-a) for
trafficking of the melanosome to the plasma membrane. Rab27a can then target and recruit
effector protein Slp2-a (also known as exophilin-4) for docking of the melanosome at the
plasma membrane [53]. Conversely, Rab27b has been shown in previous studies to
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separately target and recruit effector protein Munc13-4 for calcium-dependent exocytosis.
Specifically, effector protein Munc13-4 can catalyze the conformational change of
Syntaxin-11, from a closed complex with Munc18-2 into the ternary SNARE bundle [7].
Munc13-4 can also promote the proper Syntaxin-11/VAMP-2 configuration during ternary
bundle assembly [67]. In cooperation with Munc18-2, Munc13-4 may be able to ensure the
proper Syntaxin-11/SNAP-23 arrangement within this ternary bundle [67], [91]. The
Munc13-4 binding domain has been previously mapped to the N-terminal domain of
Rab27b, between its C2A domain and MUN domain (amino acids 240 to 543) [92].
In this study, Rab27b T23N, N133I, and Q78L mutants were utilized. Rab27b T23N and
N133I are dominant-negative mutants of Rab27b, conferring Rab27b proteins that are
defective in binding GTP. Rab27b T23N and N133I are therefore always inactive and as
such, cannot interact with effector Munc13-4 to enable calcium-dependent exocytosis to
occur. Conversely, Rab27b Q78L is a constitutively-active mutant, conferring a Rab27b
protein that is defective in GTP hydrolysis. Rab27b Q78L is therefore always active and as
such, continuously interacts with Munc13-4 to enable calcium-dependent exocytosis to
occur [93].
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Figure 2 – Small GTPase Rab27b switches between inactive and active forms
Guanine exchange factors (GEFs) catalyze the conversion from inactive Rab27b (bound to
GDP) to active Rab27b (bound to GTP) by reducing the affinity of the Rab27b-binding site
for GDP. Active Rab27b can subsequently interact with Munc13-4 to enable calciumdependent exocytosis to occur. GTPase-activating proteins (GAPs) catalyze the conversion
from active Rab27b to inactive Rab27b by promoting GTP hydrolysis. Adapted from [94].
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1.4 Alzheimer’s Disease
1.4.1 Dementia
Dementia is a syndrome that can be medically defined as cognitive dysfunction that is
severe enough to interfere with occupational and/or social functioning. These cognitive
dysfunctions include varying degrees of impairment in memory, reasoning, planning,
language, and/or visuospatial function [95]. Dementia begins when cells in certain regions
of the brain lose their synapses and consequently lose the ability to communicate with one
another [96], [97]. For example, loss of synapses within the hippocampus can impact one’s
spatial memory [98], [99]. Abuse of alcohol [100], traumatic brain injuries [101], and
neurodegenerative diseases [102] can all lead to some form of dementia. In cases such as
alcohol abuse, removing the initial cause of the dementia may prevent further cell damage,
but will not result in improvement of cognitive symptoms [100]. Despite the existence of
medications that may temporarily ease cognitive and coinciding psychological symptoms,
dementia experienced as an effect of a neurodegenerative disease is not only irreversible,
it is also progressive in its severity [102].
1.4.2 Overview of Alzheimer’s Disease
Alzheimer’s disease (AD) is a neurodegenerative disease that accounts for approximately
70% of dementia cases worldwide [103]. As such, AD is the most prevalent form of
dementia. The greatest risk factor for development of AD is increasing age [104]; after the
age of 65, the risk for developing AD doubles every five years [103].
AD was first described by Dr. Alois Alzheimer in a 51-year-old woman named Auguste
Deter. Auguste was an asylum patient who displayed various symptoms of dementia,
including short-term memory loss and language impairment [105], [106]. After her death
in 1906, Dr. Alzheimer was able to examine histological sections of Auguste’s brain using
Bielschowsky’s silver stain [105]. In addition to extensive cortical atrophy, he observed
intracellular fibril bundles and extracellular aggregates within her brain [106].
Respectively, these deposits have since been established as intracellular neurofibrillary
tangles comprised of hyperphosphorylated protein tau and extracellular plaques comprised
of aggregated protein beta-Amyloid (A) [107]. In addition to modern psychological and
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neurological testing, the only method of conclusively diagnosing an individual with AD
requires post-mortem examination of the brain using methods similar to those used by Dr.
Alzheimer over 100 years ago, for observation of both A and tau deposits [108], [109].
Since the findings of Dr. Alzheimer, intracellular neurofibrillary tangles have been
characterized to be present in association cortices and limbic areas (such as the
hippocampus) of affected individuals [110], while extracellular amyloid plaques have been
characterized to be present diffusely, throughout the cerebral cortex [111]. The
topographical pattern of neurofibrillary tangle burden in particular has been observed to be
closely coupled to the atrophy of associated brain regions. From mild (early) to severe (late)
AD stages, neurofibrillary tangle burden and associated atrophy can first be detected in
entorhinal and perirhinal cortices, then in the hippocampus, then in association cortices,
and ultimately in the primary neocortex [109], [112].
Presently, there is no curative treatment for AD [113]. As mentioned in Section 1.4.1,
medications that exist for neurodegenerative diseases today are only able to ameliorate
certain psychological and cognitive symptoms, while regions of the brain continue to
atrophy [114], [115]. Neurotransmitter acetylcholine (ACh) has previously been the focus
of many drug trials, due to the established role of ACh in the encoding of new episodic
memories [116]. In addition, many studies related to AD have observed deficits in the
cholinergic system. These observations include lack of cholinergic neurotransmission to
the cerebral cortex due to degeneration of cholinergic neurons in the nucleus basalis of
Meynert [117], and declines in synthesis of ACh mediated by choline acetyltransferase
(ChAT) due to reductions in the expression of this enzyme [118]. Thus, medications to
inhibit the function of enzyme acetylcholinesterase (AChE) were developed to prevent the
AChE-mediated breakdown of ACh into acetate and choline, and in turn increase amount
of ACh available within neuronal synaptic clefts [119]. While alleviating symptoms of
dementia, these medications did not target the underlying cause of AD and as such, studies
related to this neurodegenerative disease continue to be conducted worldwide to this day
[113].
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1.4.3 Pathogenesis of Alzheimer’s Disease
The most widely accepted theories regarding the pathophysiology of AD center around
proteins tau and A. Many researchers believe that the development of AD ensues with the
hyperphosphorylation of tau (the tau hypothesis) [120]. However, strong evidence supports
the theory that AD begins with the generation of soluble Aβ monomers from Amyloid
Precursor Protein (APP; the amyloid cascade hypothesis) [121].
APP is a Type I (single-pass) TM protein that is present in all cells. After it is produced
within the ER and processed within the TGN, APP can be trafficked to the plasma
membrane via constitutive exocytosis. Also present as a TM protein at the plasma
membrane is enzyme -secretase, a type of ADAM (a disintegrin and metalloprotease
domain) protein [122]. Co-localization of APP and -secretase on the plasma membrane
of a cell results in progression of the non-amyloidogenic pathway: constitutive -secretasemediated cleavage of APP at its Lys16-Leu17 bond and subsequent formation of sAPP
[122], [123]. sAPP is a soluble fragment of APP that is released to the extracellular space
and has been shown in many studies to elicit neuroprotective benefits, such as defence
against excitotoxic insults [124], [125]. APP cleavage can also be mediated via the
amyloidogenic pathway, which conversely results in formation of toxic peptide A. In
accordance with the amyloidogenic pathway, APP can be internalized via clathrin-mediated
endocytosis or pinocytosis prior to cleavage by -secretase at the plasma membrane [126],
[127]. Following the endocytic pathway, internalized APP can be sorted to early
endosomes, late endosomes/MVBs, and lysosomes [126]–[128]. Similarly present as a TM
protein anchored to the membranes of late endosomes/MVBs and lysosomes is the enzyme
β-secretase. β-secretase, also known as β-site APP-cleaving enzyme 1 (BACE1), is an
aspartyl protease [129]. It contains one active site with two aspartic acid residues that are
each present at a characteristic motif; therefore, β-secretase has previously been suggested
to function as a dimer (with each monomer providing one aspartic acid residue) [130].
Although β-secretase can also be found at the early endosome and plasma membrane, it
functions optimally at an acidic pH of approximately 4.5. Therefore, the activity of βsecretase is most likely restricted to acidic late endosomes/MVBs and lysosomes [131]. As
the active site of β-secretase is targeted toward the lumens of the organelles that it is
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localized to, β-secretase-mediated cleavage of APP results in formation and release of
soluble fragment sAPPβ into the lumens of late endosomes/MVBs and lysosomes. This
process leaves behind a TM C-terminal fragment (CTF) known as β-CTF, or C99 [129].
Cleavage of C99 and subsequent formation of Aβ is now dependent on a TM complex
referred to as γ-secretase (Figure 3). The γ-secretase complex is comprised of at least four
subunits, including presenilin (PS) 1 or 2, nicastrin, anterior pharynx-defective 1 (APH-1),
and presenilin enhancer 2 (PEN-2) [132]. PS has previously been observed to contain the
critical catalytic subunit of γ-secretase. Catalysis is specifically dependent on two
conserved aspartates in the sixth and seventh TM domains of each PS homologue. Akin to
β-secretase, γ-secretase thus functions as an aspartyl protease [133]. Unlike β-secretase,
however, γ-secretase presents with a “spatial paradox”: although γ-secretase has been
localized to the ER and Golgi apparatus, the production of Aβ has been observed at the
plasma membrane, late endosomes/MVBs, and lysosomes [134]. Furthermore, there is
presently little consensus regarding the pH optimum of γ-secretase activity. Enzymatic
activity has been observed at a neutral pH of approximately 7.0 [135], at a broad range of
pH 6.0-8.4 [136], and even at an acidic pH of approximately 4.5 [134]. Despite this spatial
paradox, most researchers believe that the majority of Aβ production is dependent on
internalization of APP from the plasma membrane. In particular, inhibiting clathrinmediated internalization of APP by altering endocytic signal sequences or blocking scission
of vesicles can reduce Aβ production by 70% [127], [137]. Inhibiting pinocytosis similarly
decreases Aβ production by more than 30% [126]. In addition, strong evidence suggests
that this Aβ production occurs specifically within lysosomes. For example, knockdown of
PS1 results in accumulation of C99 at the lysosomal membrane [138]. Acidic pH has also
been shown to promote the formation and aggregation of Aβ [3], [139], with exogenous Aβ
observed to accumulate specifically within the lysosomal lumen [140]. Ultimately, it is
likely that γ-secretase-mediated cleavage of C99 and subsequent production of Aβ occurs
at the plasma membrane, late endosomes/MVBs, and lysosomes to varying degrees.
Cleavage by γ-secretase is imprecise and can occur at multiple sites of C99. This results in
the production of soluble Aβ peptide monomers that vary in length, from 39 to 43 amino
acids. The most common variants of Aβ that are generated in a given cell are Aβ40 and
Aβ42, with Aβ40 comprising approximately 80-90% of all Aβ produced and Aβ42 comprising
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approximately 5-10% of all Aβ produced [1]. Regardless of length, all Aβ monomers
possess the intrinsic ability to aggregate. This ability is attributable to hydrophobic residues
present at the C-terminal domain of the peptide. Although it is less abundant, Aβ42 contains
two additional hydrophobic amino acids at its C-terminal domain, which enhance the
propensity of Aβ42 to aggregate in comparison to Aβ40. Aβ42 is therefore the most prevalent
Aβ variant found in amyloid plaques [141], [142]. Aggregation of Aβ can also result in the
formation of oligomers and fibrils. Of these species, oligomers in particular have been
implicated in neurotoxicity and associated cell death [143]. Due to its hydrophobicity, Aβ
has also been shown to associate with the lipid bilayer and associated lipids rafts of the
plasma membrane [144], [145]. Lipid rafts are ordered microdomains of membranes that
contain cholesterol and sphingolipids [145], and have been shown in previous studies to
facilitate the formation of Aβ oligomers at the plasma membrane [146]. Association of Aβ
oligomers

with

lipid

rafts

can

induce

neurotoxicity

indirectly

through

hyperphosphorylation of protein tau [146]–[148].
Tau is a microtubule-associated protein (MAP) necessary for the assembly and stabilization
of microtubules within cells. Microtubules are rigid components of the cytoskeleton that
are required to maintain a cell’s shape and structure [149]. After it is expressed, tau is able
to undergo many post-translational modifications that alter its interaction with
microtubules, including phosphorylation [150], [151]. Phosphorylation of tau is
dynamically regulated by the enzymatic activity of kinases, which catalyze the addition of
a phosphate group, and phosphatases, which catalyze the removal of a phosphate group
[151]. Phosphorylation of tau has been shown in previous studies to negatively regulate its
association with microtubules. Tau hyperphosphorylation would therefore result in a
drastic decrease in the ability of tau to bind to microtubules, and its intrinsic ability to
aggregate with itself and other MAPs would increase in propensity [152], [153]. This would
ultimately decrease the stability of the cell and result in cell death [154]. This would also
result in the formation of the primary component of neurofibrillary tangles: paired helical
filaments (PHFs) [153]. Tau hyperphosphorylation can occur through upregulation of
kinases, downregulation of phosphatases, and altered post-translational modifications of
kinases (such as decreased O-GlcNAcylation) that increase kinase activity [152], [155]. As
mentioned above, hyperphosphorylation of tau can also occur upon binding of Aβ to lipid
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rafts [146]. Binding of Aβ to lipid rafts forms pores in the plasma membrane [147], which
can enable large amounts of extracellular Ca2+ to enter the cell. An excessive influx of Ca2+
can result in the persistent activation of tau kinases and succeeding tau
hyperphosphorylation [148]. Activation of N-methyl-D-aspartate (NMDA) receptors by
Aβ, potentially through interactions with lipid rafts [146], [156], can similarly induce influx
of Ca2+ and subsequent activation of tau kinases [157].
Additional support for the amyloid cascade hypothesis emerged after the discovery of
early-onset forms of AD termed Familial AD (FAD). FAD can surface as a direct result of
underlying autosomal dominant mutations in PSEN1, PSEN2, or APP genes [158].
Approximately 1% to 5% of all AD cases are attributed to mutations in these genes [159],
[160], which respectively encode proteins PS1, PS2, and APP. While mutations in PSEN1
or PSEN2 increase the propensity of γ-secretase to produce Aβ42 in particular, mutations in
APP increase the amount of overall Aβ produced [158]. As the APP gene is found on
chromosome 21, individuals with Trisomy 21 (Down syndrome) are similarly likely to
develop AD due to overexpression of APP and increased production of Aβ [161], [162].
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Figure 3 – Processing of APP
Following the amyloidogenic pathway, cleavage of APP by β-secretase leads to the
production of soluble fragment sAPPβ and membrane-bound C99. Consecutive cleavage
by γ-secretase generates Aβ and APP intracellular domain (AICD). Following the nonamyloidogenic pathway, α-secretase-mediated cleavage of APP produces soluble fragment
sAPPα and membrane-bound C83. Consecutive cleavage by γ-secretase generates p3
peptide and AICD. Cleavage of APP by α-secretase thus precludes the generation of Aβ.
Adapted from [163].
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1.5 Rationale
1.5.1 Overview
AD can be characterized in post-mortem brain samples by the presence of both extracellular
Aβ plaques and intracellular neurofibrillary tau tangles [108], [109]. While many
researchers agree that Aβ plays a critical early role in the progression of AD, it is not clear
how this protein can be found within extracellular amyloid plaques.
Aβ is generated by β- and γ-secretase-mediated cleavage of TM protein APP [163]. APP
can be internalized from the plasma membrane and subsequently trafficked to lysosomes
directly [126], [128], or indirectly via the endocytic pathway [127]. Co-localization of APP,
active β-secretase, and active γ-secretase at late endosomes/MVBs and lysosomes results
in the production of soluble Aβ monomers within these compartments [134]. Aβ generated
in late endosomes/MVBs can also be trafficked to lysosomes via fusion of lysosomes with
late endosomes/MVBs [33].
Studies have shown that Aβ can not only be generated within and trafficked amongst late
endosomes/MVBs and lysosomes, it can also aggregate and be resistant to degradation
within these compartments. For example, Aβ42 can aggregate within cultured neuronal cells
at a higher rate and to a greater extent at an acidic pH in comparison to a more basic pH
[3]. Apart from the ability to break down materials, lysosomes have recently been shown
to have the ability to undergo calcium-dependent exocytosis. This was observed by one
group upon an increase in fluorescence of lysosomal markers in the presence of
extracellular Ca2+, but no change in fluorescence of the same lysosomal markers in the
presence of calcium chelator ethylene glycol bis(2-aminoethyl)tetraacetic acid (EGTA)
[164]. Furthermore, Aβ42 has been observed to specifically accumulate within lysosomes
and late endosomes/MVBs when exocytosis was inhibited using tetanus toxin [165].
Interestingly, studies of human AD brains and AD mouse model brains have provided
evidence that lysosomal aspartyl protease cathepsin D, which is normally found within the
lumens of lysosomes, can also be found in extracellular amyloid plaques [4], [166]. Taken
together, results from previous studies provide a great deal of evidence for the existence of
lysosomes that are able to release Aβ to the extracellular space.
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Although there is no known protein that is specific to lysosomal-mediated exocytosis,
previous studies have shown that small GTPase Rab27b is one of the most important
proteins for this process. This is due to the activity of Rab27b effector protein Munc13-4.
Munc13-4 is able to interact with SNARE proteins, such as t-SNAREs Syntaxin-11 [167]
and SNAP-23 [91], to enable efficient lysosomal membrane to plasma membrane priming
during the process of calcium-dependent exocytosis [7], [9].
1.5.2 Hypothesis
It is hypothesized that secretion of Aβ is mediated by lysosomes in a Rab27b-dependent
manner (Figure 4).

Figure 4 – Aβ secretion following intracellular trafficking and processing of APP
Amyloid Precursor Protein (APP) can be internalized from the plasma membrane and
subsequently trafficked to lysosomes directly, or indirectly via the endocytic pathway. Colocalization of APP, active β-secretase, and active γ-secretase at late endosomes/MVBs and
lysosomes results in the production of soluble Aβ monomers within these compartments.
Aβ generated in late endosomes/MVBs can also be trafficked to lysosomes via fusion of
lysosomes with late endosomes/MVBs. Lysosomes can then mediate calcium- and Rab27bdependent exocytosis of Aβ.
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1.5.3 Objectives
The objectives of this study included:
1) To demonstrate storage of Aβ42 and Aβ40 within lysosomes.
2) To demonstrate lysosomal-mediated secretion of Aβ42 and Aβ40.
3) To establish the effects of Rab27b mutants on Rab27b distribution.
4) To establish the effects of Rab27b mutants on secretion of Aβ42 and Aβ40.
1.5.4 Predictions
The predictions of this study were as follows:
1) Loading of Neuro-2a (N2A) cells with exogenous Aβ40 and Aβ42 will result in
storage of exogenous Aβ42 and Aβ40 in lysosomes.
2) Initiation of calcium-dependent exocytosis with calcium ionophore ionomycin will
result in secretion of lysosome-stored exogenous Aβ42 and Aβ40.
3) There will be an increase in co-localization of Rab27b and lysosomes posttreatment with ionomycin in comparison to pre-treatment in Rab27b wild-type
(WT) samples loaded with Aβ42 or Aβ40.
4) There will be no significant differences in co-localization of Rab27b and lysosomes
post-treatment in comparison to pre-treatment in Rab27b mutant (T23N, N133I, and
Q78L) samples loaded with Aβ42 or Aβ40.
5) There will be a decrease in co-localization of Rab27b and Aβ42 or Aβ40 posttreatment in comparison to pre-treatment in Rab27b WT samples.
6) There will be no significant differences in co-localization of Rab27b and Aβ42 or
Aβ40 post-treatment in comparison to pre-treatment in Rab27b mutant samples.
7) Rab27b T23N and N133I samples will secrete significantly less Aβ42 and Aβ40 in
comparison to Rab27b WT, Q78L and control samples, when stimulated with
ionomycin.
8) Rab27b Q78L samples will secrete significantly more Aβ42 and Aβ40 in comparison
to Rab27b T23N, N133I, WT and control samples.
9) There will be no significant differences in secretion of Aβ42 in comparison to
secretion of Aβ40, in control and Rab27b samples.
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Chapter 2

2

Materials and Methods

2.1 Cell Culture
Neuro-2a (N2A; ATCC) cells were cultured in Minimum Essential Medium (MEM; Gibco)
supplemented with 10% v/v Fetal Bovine Serum (FBS; Gibco) and maintained in 5% CO2
at 37°C. On day one, 2 x 105 cells were seeded onto 35 mm uncoated glass-bottom (14 mm,
No. 1.5 coverslip) confocal dishes (MatTek) in MEM supplemented with 10% FBS. 24
hours later (day two), samples were transiently transfected using Lipofectamine 2000
(Invitrogen), according to manufacturer’s instructions. 4.5 hours later, samples were
incubated with Aβ (AnaSpec) overnight in serum-free MEM. 18 hours later (day three),
cells were either subjected to ionomycin treatment or imaged under confocal or widefield
microscopy. Cells were sub-cultured using 0.25% Trypsin-EDTA (1X; Gibco) every three
or four days.

2.2 DNA Constructs
Samples to be imaged under confocal microscopy were transiently transfected with 0.3 µg
LAMP1 tagged to monomeric Cherry Fluorescent Protein (mChFP; control samples) or 0.3
µg LAMP1-mChFP and 0.8 µg Rab27b T23N, N133I, wild-type (WT), or Q78L tagged to
Enhanced Blue Fluorescent Protein (EBFP; Rab27b samples) using Lipofectamine 2000,
according to manufacturer’s instructions. In this manner, we were able to visualize
lysosomes in control samples or lysosomes and Rab27b T23N, N133I, WT, or Q78L in
Rab27b samples.
DNA construct LAMP1-mChFP was previously cloned in our laboratory. DNA constructs
Rab27b-EBFP T23N, N133I, WT, and Q78L were newly generated via subcloning.
Specifically, Rab27b-GFP T23N, N133I, WT, and Q78L genes of interest were PCRamplified using high-fidelity KOD Hot Start DNA polymerase, according to
manufacturer’s instructions (Sigma-Aldrich). Custom primers used for this reaction
included forward primer 5’ – ATACAGATCTATGACCGATGGAGACTATGATT – 3’
(containing

a

BglII

restriction

site)

and

reverse

primer

5’

–
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ATACAAGCTTCTAGCAGATACATTTCTTCTCTGG – 3’ (containing a HindIII
restriction site) (Invitrogen). Enzymes BglII and HindIII were used for restriction site
digestion (Thermo Fisher Scientific), and digested products were respectively extracted and
purified using QIAquick Gel Extraction and PCR Purification kits (Qiagen), according to
manufacturer’s instructions. PCR products were ligated into an EBFP-C1 vector (Addgene
plasmid #54738) at a 3:1 ratio using T4 DNA ligase (New England Biolabs), and the
recombinant DNA plasmids were sequenced. These recombinant DNA plasmids were then
transformed using DH5α competent Escherichia coli cells (Thermo Fisher Scientific).
Construct Rab27b-GFP WT was provided by Dr. Reinhard Jahn (Max Planck Institute,
Munich, Germany). Rab27b-GFP T23N, N133I, and Q78L constructs were provided by
Dr. Miguel Seabra (Imperial College London, London, England).
Samples to be imaged under widefield microscopy were transiently transfected with 0.8 µg
mApple-LAMP1-pHluorin (Addgene plasmid #54918) using Lipofectamine 2000,
according to manufacturer’s instructions. This allowed us to visualize lysosomal-mediated
secretion in real-time.

2.3 Aβ40 and Aβ42 Preparation
1 mg of human HiLyte Fluor 647-labeled Aβ40 or Aβ42 (AnaSpec) was resuspended to 1
mM using 1,1,1,3,3,3-hexafluoro-2-propanol (HFIP; Sigma-Aldrich). HFIP was
evaporated using medium-speed vacuum centrifugation at room temperature for one hour,
yielding Aβ40 or Aβ42 peptide films. To generate non-aggregates (peptide monomers),
peptide films were resuspended to 1 mM using dimethyl sulfoxide (DMSO; SigmaAldrich) and exposed to bath sonication at room temperature for 15 minutes. Nonaggregates were diluted to 100 µM with ice-cold Dulbecco’s phosphate-buffered saline
(DPBS; Sigma-Aldrich) and vortexed immediately for 30 seconds. Aliquots of nonaggregates were stored at -80°C until use.
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2.4 Ionomycin Treatment
1 µM ionomycin (Sigma-Aldrich) was added to live N2A cells 18 hours after incubation
with Aβ (day three), either bench-side (prior to confocal microscopy) or at the microscope
(during widefield microscopy). Bench-side samples were immediately fixed using 4%
paraformaldehyde (PFA; Alfa Aesar) after two minutes of treatment with ionomycin.
Widefield microscopy samples were discarded after treatment with ionomycin (after timelapse videos were recorded).

2.5 Confocal Microscopy
Cells were imaged under confocal microscopy using a Leica TCS SP8 inverted microscope
(Leica Camera AG, Wetzlar, Germany) operated by Leica LAS X Software, before (livecell microscopy) and after (fixed-cell microscopy) treatment with ionomycin. All pre- and
post-treatment images, including Z-stack images, were acquired using an HC PL APO CS2
63x / 1.40 oil objective. A 50 mW DMDO diode laser was used to excite wavelengths of
405 nm (HyD detector; EBFP fluorophore). A 20 mW AOTF diode laser was used to excite
wavelengths of 552 nm (PMT detector; mChFP fluorophore). A 30 mW AOTF diode laser
was used to excite wavelengths of 638 nm (HyD detector; HiLyte Fluor 647 fluorophore).
30-frame Z-stack images were acquired at section intervals of 0.1 µm.

2.6 Widefield Microscopy
Live cells were imaged under widefield microscopy using a Leica DMI6000B inverted
microscope (Leica Camera AG, Wetzlar, Germany) operated by Leica LAS X Software.
Time-lapse videos were acquired using an HC PL APO 100x / 1.40 oil objective and a
Hamamatsu Photometrics Delta EvOLVE EM-CCD camera. An EL6000 metal-halide
lamp was used to excite wavelengths of 535 nm (FITC filter cube; ecliptic pHluorin
fluorophore), 605 nm (CY3 filter cube; mApple fluorophore), and 705 nm (CY5 filter cube;
HiLyte Fluor 647 fluorophore). Samples were placed on a heated and CO2-perfused stage.
1 µM ionomycin was added to each sample five seconds after start of time-lapse. Timelapse videos were recorded for a length of five minutes, and images were acquired at an
interval of 0.341 seconds between frames.
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2.7 Co-Localization Analyses
Before undergoing co-localization analyses, images of cells taken using the Leica TCS SP8
confocal microscope were first chosen for co-localization analyses. Criteria for choosing a
pre-treatment cell required the cell to appear: 1) well-transfected with LAMP1-mChFP (in
control samples) or LAMP1-mChFP and Rab27b-EBFP WT, Q78L, T23N, or N133I (in
Rab27b samples), and 2) well-loaded with HiLyte Fluor 647-labeled Aβ40 or Aβ42. Criteria
for choosing a post-treatment cell required the cell to: 1) appear well-transfected with
LAMP1-mChFP (in control samples) or LAMP1-mChFP and Rab27b-EBFP WT, Q78L,
T23N, or N133I (in Rab27b samples), and 2) contain HiLyte Fluor 647-labeled Aβ40 or
Aβ42 within the field of vision of the cell (intracellular and/or extracellular).
Imaris Software 7 (Bitplane) was used to conduct all co-localization analyses (Appendix
1). This included co-localization of: 1) HiLyte Fluor 647-labeled Aβ40 or Aβ42 and LAMP1mChFP (control and Rab27b samples), 2) Rab27b-EBFP (T23N, N133I, WT, or Q78L)
and LAMP1-mChFP (Rab27b samples), and 3) Rab27b-EBFP (T23N, N133I, WT, or
Q78L) and HiLyte Fluor 647-labeled Aβ40 or Aβ42 (Rab27b samples). Co-localization can
be defined as the occurrence of two fluorochromes in one location. Imaris measures colocalization using a method founded by Costes and Lockett (NIH, NCI/SAIC). This method
considers the degree of overlap of two channels by measuring fluorescence intensity of
voxels. As such, Imaris automatically corrects for differences in high- and low-intensity
voxels (Coloc intensity option: Source channels), rather than simply measuring number of
overlapping voxels. Imaris furthermore enables the user to manually set a threshold for
percent of data that will be used for signal analysis. To allow for datasets to be compared
amongst one another, the threshold set for each channel (green channel: LAMP1-mChFP;
red channel: Aβ42 and Aβ40; blue channel: Rab27b-EBFP T23N, N133I, WT and Q78L)
remained constant throughout all analyses that were conducted.
A co-localization channel was built using the specified settings, producing a variety of
statistical values. The statistical values used for the purposes of this study were:
“percentage of channel A material above threshold A that is co-localized” and “percentage
of channel B material above threshold B that is co-localized”. Use of the former or latter
value was dependent on the two channels in question. For example, “percentage of channel
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A material above threshold A that is co-localized” was used for co-localization analysis of
the red channel (Aβ) and green channel (LAMP1-mChFP) when the red channel was
introduced to the module as channel A. Imaris consequently analyzed, “percentage of Aβ
above threshold A that is co-localized with LAMP1-mChFP” instead of “percentage of
LAMP1-mChFP above threshold B that is co-localized with Aβ”. This statistical value was
considered the raw data for all subsequent analyses.

2.8 Statistical Analyses
Before statistical analyses were completed, all post-treatment raw data was placed under
an exclusion criterion. This exclusion criterion was specific to each corresponding pre- and
post-treatment dataset and was regarded as the mean of the pre-treatment raw data. This
mean was considered the threshold for exocytosis and as such, any corresponding posttreatment raw data value that was at or above the threshold was excluded from the
subsequent statistical analyses, as the cell did not undergo exocytosis. For example, if the
mean co-localization percentage of LAMP1-mChFP and Aβ42 in control samples was 40%
pre-treatment (raw), any co-localization value at or above 40% within the corresponding
post-treatment dataset (raw) would be excluded from statistical analyses.
In order to be able to compare between datasets, post-treatment raw data was normalized
to corresponding pre-treatment raw data. GraphPad Prism 8 was used to normalize raw data
as follows: 1) Each pre-treatment value within a dataset was normalized to 100% by setting
0% as 0 and setting 100% as the mean of the pre-treatment raw data, 2) Each post-treatment
value was normalized to its corresponding pre-treatment data by setting 0% as 0 and setting
100% as Y=mean of the pre-treatment raw data. When comparing between pre-treatment
datasets, pre-treatment raw data was not normalized.
All subsequent statistical analyses were again performed using GraphPad Prism 8. All
groups were tested with a Shapiro-Wilk normality test. An unpaired t-test with Welch’s
correction was conducted when determining whether there was a statistically significant
difference between pre- and post-treatment normalized data, within a dataset. Welch’s
correction was necessary to correct for unequal variances within a dataset. A BrownForsythe and Welch’s one-way Analysis of Variance (ANOVA) followed by a post hoc
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Dunnett’s T3 multiple comparison test was conducted when determining whether there was
a statistically significant difference between pre- or post-treatment normalized data,
between datasets. Brown-Forsythe and Welch’s corrections were necessary to correct for
unequal variances between datasets.
All data herein is expressed as mean ± standard error of the mean (SEM). p<0.05 was
considered a minimum critical value for statistical significance throughout this study.
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Results

3.1 Exogenous Aβ Accumulates Within Lysosomes
To demonstrate storage of Aβ within lysosomes, live N2A cells that were transfected with
LAMP1-mChFP and loaded with exogenous Aβ were imaged under confocal microscopy.
Acquired images were used to calculate percent co-localization of LAMP1-mChFP and
HiLyte Fluor 647-labeled Aβ42 or Aβ40 using Imaris Software 7. In Imaris, a signal intensity
threshold of the top 2% of the data was chosen for the green channel (LAMP1-mChFP),
because lysosome burden within mammalian cells ranges from 1% to 15% [168].
Thresholding the top 2% of voxels omitted signals that might have arisen from low amounts
of newly-synthesized LAMP1 found in the ER, Golgi apparatus, and/or late
endosomes/MVBs [20], [21]. Conversely, Aβ signal was very bright and appeared to
display a restricted pattern of localization (to lysosomes or to the plasma membrane).
However, as Aβ cell burden can vary widely depending on the amount of Aβ that is
internalized by the cell and the amount of Aβ that is secreted, the signal threshold for Aβ
needed to be determined empirically across many images. To capture the majority of Aβ
that was internalized or secreted, a signal intensity threshold range of the top 0.5% to 2%
of the data was chosen for the red channel (Aβ42 and Aβ40).
3.1.1 Intracellular Aβ Localization
51.86% ± 0.93% of HiLyte Fluor 647-labeled Aβ42 co-localized with LAMP1-mChFP
within N2A cells, prior to treatment with ionomycin (N=3, n=141) (Figure 5 and Figure 7).
Similarly, 34.44% ± 2.58% of HiLyte Fluor 647-labeled Aβ40 co-localized with LAMP1mChFP within N2A cells, prior to treatment with ionomycin (N=5, n=106) (Figure 6 and
Figure 7). Therefore, Aβ can accumulate within lysosomes.

Pre-treatment
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Figure 5 – Co-localization of LAMP1-mChFP and Aβ42
LAMP1-mChFP and HiLyte Fluor 647-labeled Aβ42 co-localized in N2A cells pretreatment with ionomycin. Conversely, LAMP1-mChFP and HiLyte Fluor 647-labeled
Aβ42 did not co-localize in N2A cells post-treatment with ionomycin. White outlines
represent the plasma membranes of N2A cells. Blue arrowheads highlight extracellular
accumulations of HiLyte Fluor 647-labeled Aβ42 proximal to the plasma membrane (posttreatment). Scale bars represent 5 µm.

Pre-treatment

35

5 µm

5 µm

5 µm

10 µm

10 µm

10 µm

10 µm

Post-treatment

5 µm

Figure 6 – Co-localization of LAMP1-mChFP and Aβ40
LAMP1-mChFP and HiLyte Fluor 647-labeled Aβ40 co-localized within N2A cells pretreatment with ionomycin. Conversely, LAMP1-mChFP and HiLyte Fluor 647-labeled
Aβ40 did not co-localize within N2A cells post-treatment with ionomycin. White outlines
represent the plasma membranes of N2A cells. Blue arrowheads highlight extracellular
accumulations of HiLyte Fluor 647-labeled Aβ40 proximal to the plasma membrane (posttreatment). Pre-treatment scale bars represent 5 µm. Post-treatment scale bars represent 10
µm.
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Figure 7 – Pre-treatment co-localization of LAMP1-mChFP and Aβ
There were no significant differences in LAMP1-mChFP and HiLyte Fluor 647-labeled Aβ
co-localization between Aβ42 and Aβ40 samples, as determined by Brown-Forsythe and
Welch ANOVA tests followed by post hoc Dunnett’s T3 multiple comparisons tests. All
results are presented as raw mean ± SEM.
3.1.2 Between-Group Comparison
To determine whether there was a difference in Aβ loading between Aβ42 and Aβ40 samples,
pre-treatment percent co-localization of LAMP1-mChFP and HiLyte Fluor 647-labeled
Aβ42 (51.86% ± 0.93%), and pre-treatment percent co-localization of LAMP1-mChFP and
HiLyte Fluor 647-labeled Aβ40 (34.44% ± 2.58%) were compared. Raw pre-treatment data
was subjected to Brown-Forsythe and Welch ANOVA tests followed by post hoc Dunnett’s
T3 multiple comparisons tests. There were no significant differences pre-treatment with
ionomycin when comparing between Aβ42 (N=3, n=141) and Aβ40 (N=5, n=106) groups.
Therefore, there was no significant difference in Aβ loading between samples (Figure 7).
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3.2 Aβ Secretion is Mediated by Lysosomes
To quantitatively demonstrate lysosomal-mediated secretion of Aβ, N2A cells that were
transfected with LAMP1-mChFP and loaded with exogenous Aβ were treated with
ionomycin, fixed, and imaged under confocal microscopy. Images acquired pre- and posttreatment with ionomycin were used to calculate percent co-localization of LAMP1mChFP and HiLyte Fluor 647-labeled Aβ42 or Aβ40 using Imaris Software 7. A signal
intensity threshold of the top 2% of the data was used for LAMP1-mChFP, and a signal
intensity threshold range of the top 0.5% to 2% of the data was used for Aβ. The raw mean
co-localization percentages of LAMP1-mChFP and HiLyte Fluor 647-labeled Aβ were as
follows: 51.86% ± 0.93% in pre-treatment Aβ42 samples, 34.44% ± 2.58% in pre-treatment
Aβ40 samples (Figure 7), 6.28% ± 1.30% in post-treatment Aβ42 samples, and 8.41% ±
1.91% in post-treatment Aβ40 samples (data not shown). To qualitatively observe
lysosomal-mediated secretion of Aβ, N2A cells that were transfected with mAppleLAMP1-pHluorin and loaded with exogenous Aβ were treated with ionomycin during livecell widefield microscopy (data not shown).
3.2.1 Within-Group Comparison
To determine whether Aβ42 and Aβ40 peptides undergo lysosomal-mediated secretion, pretreatment percent co-localization of LAMP1-mChFP and HiLyte Fluor 647-labeled Aβ42
or Aβ40 was compared to post-treatment percent co-localization of LAMP1-mChFP and
HiLyte Fluor 647-labeled Aβ42 or Aβ40. Normalized data was subjected to unpaired t-tests
with Welch’s correction. LAMP1-mChFP and HiLyte Fluor 647-labeled Aβ42 colocalization significantly decreased post-treatment (N=3, n=48) with ionomycin in
comparison to pre-treatment (N=3, n=141) (p<0.0001) (Figure 5). This was an 87.89% ±
3.09% decrease in co-localization (Figure 8). Similarly, LAMP1-mChFP and HiLyte Fluor
647-labeled Aβ40 co-localization significantly decreased post-treatment (N=3, n=37) with
ionomycin in comparison to pre-treatment (N=5, n=106) (p<0.0001) (Figure 6). This was
a 75.58% ± 9.32% decrease in co-localization (Figure 8). Therefore, Aβ42 and Aβ40 peptides
underwent significant lysosomal-mediated secretion. Interestingly, secreted Aβ42 and Aβ40
peptides were observed to accumulate proximal to the plasma membranes of N2A cells
(Figure 5 and Figure 6).
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3.2.2 Between-Group Comparison
To determine whether there was a difference in lysosomal-mediated secretion of Aβ42 and
Aβ40, post-treatment percent co-localization of LAMP1-mChFP and HiLyte Fluor 647labeled Aβ42 was compared to post-treatment percent co-localization of LAMP1-mChFP
and HiLyte Fluor 647-labeled Aβ40. Normalized post-treatment data was subjected to
Brown-Forsythe and Welch ANOVA tests followed by post hoc Dunnett’s T3 multiple
comparisons tests. There were no significant differences post-treatment with ionomycin
when comparing between Aβ42 (N=3, n=48) and Aβ40 (N=3, n=37) groups (Figure 8).
Therefore, there was no difference in lysosomal-mediated secretion of Aβ42 and Aβ40.
LAMP1-mChFP and AB Co-Localization

Figure 8 – Mean co-localization of LAMP1-mChFP and Aβ
LAMP1-mChFP and HiLyte Fluor 647-labeled Aβ42 co-localization significantly decreased
post-treatment (N=3, n=48) with ionomycin in comparison to pre-treatment (N=3, n=141)
(p<0.0001). Similarly, LAMP1-mChFP and HiLyte Fluor 647-labeled Aβ40 co-localization
significantly decreased post-treatment (N=3, n=37) with ionomycin in comparison to pretreatment (N=5, n=106) (p<0.0001). There were no significant differences pre- or posttreatment with ionomycin when comparing between Aβ42 and Aβ40 groups. Dark bars
indicate pre-treatment with ionomycin, and light bars indicate post-treatment with
ionomycin. All results are presented as normalized mean ± SEM. Asterisks indicate
statistically significant changes post-treatment with ionomycin in comparison to pretreatment, as determined by unpaired t-tests with Welch’s correction. ****p<0.0001
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3.3 Subcellular Distribution of Rab27b
To establish the effects of Rab27b mutants on Rab27b distribution, N2A cells that were
transfected with LAMP1-mChFP and Rab27b-EBFP WT, Q78L, T23N, or N133I and
loaded with exogenous Aβ were imaged under confocal microscopy before and after
treatment with ionomycin. Images acquired pre- and post-treatment with ionomycin were
used to calculate percent co-localization of Rab27b-EBFP and LAMP1-mChFP or Rab27bEBFP and Aβ using Imaris Software 7. A signal intensity threshold of the top 2% of the
data was chosen for LAMP1-mChFP, and a signal intensity threshold range of the top 0.5%
to 2% of the data was chosen for Aβ. Although there has been no research to date regarding
Rab27b cell burden, the majority of inactive Rab27b (WT) should be present diffusely in
the cytoplasm, and the majority of active Rab27b (WT) should be localized to lysosomal
membranes or the plasma membrane [169]. A signal intensity threshold range of the top
2% to 5% of the data for the blue channel (Rab27b-EBFP T23N, N133I, WT, and Q78L)
was therefore required to capture the broad distribution of Rab27b. This threshold range
was established empirically across many images. The raw mean co-localization percentages
of Rab27b-EBFP and LAMP1-mChFP in Rab27b samples are listed in Table 1. The raw
mean co-localization percentages of Rab27b-EBFP and Aβ in Rab27b samples are listed in
Table 2.
Table 1 – Raw mean co-localization of Rab27b-EBFP and LAMP1-mChFP
Aβ

Aβ42

Aβ40

Rab27b
T23N
N133I
WT
Q78L
T23N
N133I
WT
Q78L

Pre-treatment
Co-localization (%)
6.61 ± 0.58
6.95 ± 0.48
9.53 ± 0.74
10.88 ± 0.97
6.51 ± 0.97
6.68 ± 0.86
10.68 ± 1.31
12.57 ± 0.49

Post-treatment
Co-localization (%)
5.40 ± 0.50
7.52 ± 1.02
9.17 ± 0.18
11.15 ± 1.52
4.31 ± 0.28
5.25 ± 0.40
10.03 ± 1.12
14.24 ± 1.60
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Table 2 – Raw mean co-localization of Rab27b-EBFP and Aβ
Aβ

Aβ42

Aβ40

Rab27b
T23N
N133I
WT
Q78L
T23N
N133I
WT
Q78L

Pre-treatment
Co-localization (%)
10.82 ± 0.45
13.55 ± 1.50
16.48 ± 1.05
17.71 ± 3.28
10.80 ± 3.49
9.69 ± 0.77
18.57 ± 2.87
18.26 ± 1.56

Post-treatment
Co-localization (%)
10.59 ± 3.66
9.92 ± 2.07
10.72 ± 2.72
8.60 ± 1.91
5.72 ± 1.35
6.42 ± 0.93
9.11 ± 2.53
12.65 ± 3.09

3.3.1 No Differences in Rab27b and Lysosome Co-Localization
To determine whether there was a difference in co-localization of Rab27b and lysosomes
in Aβ42 and Aβ40 groups, raw pre- and normalized post-treatment datasets were subjected
to unpaired t-tests with Welch’s correction, in addition to Brown-Forsythe and Welch
ANOVA tests followed by post hoc Dunnett’s T3 multiple comparisons tests. There were
no significant differences in pre- and/or post-treatment co-localization of Rab27b-EBFP
and LAMP1-mChFP in Aβ42 and Aβ40 groups amongst all Rab27b samples (Rab27b T23N,
N133I, WT, and Q78L) (Figure 9 and Figure 10).
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Figure 9 – Co-localization of LAMP1-mChFP and Rab27b-EBFP
Co-localization of LAMP1-mChFP and Rab27b-EBFP in HiLyte Fluor 647-labeled Aβ42
and Aβ40 samples pre- and post-treatment with ionomycin. White outlines represent the
plasma membranes of N2A cells. Scale bars represent 5 µm.
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A

AB-42: LAMP1-mChFP and Rab27b-EBFP Co-Localization

B

AB-40: LAMP1-mChFP and Rab27b-EBFP Co-Localization

Figure 10 – Mean co-localization of LAMP1-mChFP and Rab27b-EBFP
There were no significant differences in pre- and/or post-treatment co-localization of
LAMP1-mChFP and Rab27b-EBFP in (A) Aβ42 and (B) Aβ40 groups amongst all Rab27b
samples, as determined by unpaired t-tests with Welch’s correction, in addition to BrownForsythe and Welch ANOVA tests followed by post hoc Dunnett’s T3 multiple
comparisons tests. Dark bars indicate pre-treatment with ionomycin, and light bars indicate
post-treatment with ionomycin. All results are presented as normalized mean ± SEM.
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3.3.2

Differences in Rab27b and Aβ Co-Localization

To determine whether there was a difference in co-localization of Rab27b and Aβ amongst
Rab27b samples (Rab27b T23N, N133I, WT, and Q78L), raw pre- and normalized posttreatment datasets were subjected to unpaired t-tests with Welch’s correction, in addition
to Brown-Forsythe and Welch ANOVA tests followed by post hoc Dunnett’s T3 multiple
comparisons tests. Rab27b-EBFP Q78L and HiLyte Fluor 647-labeled Aβ42 co-localization
significantly decreased post-treatment (N=5, n=28) with ionomycin in comparison to pretreatment (N=7, n=36) (p<0.05). This was a 51.46% ± 21.45% decrease in co-localization
(Figure 11 and Figure 12A). Rab27b-EBFP N133I and HiLyte Fluor 647-labeled Aβ40 colocalization significantly decreased post-treatment (N=5, n=35) with ionomycin in
comparison to pre-treatment (N=5, n=40) (p<0.05). This was a 33.77% ± 12.48% decrease
in co-localization. Rab27b-EBFP WT and HiLyte Fluor 647-labeled Aβ40 co-localization
significantly decreased post-treatment (N=6, n=42) with ionomycin in comparison to pretreatment (N=7, n=28) (p<0.05). This was a 50.92% ± 20.61% decrease in co-localization
(Figure 11 and Figure 12B). There were no significant differences in co-localization of
Rab27b and Aβ42 or Aβ40 between Rab27b samples.
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Figure 11 – Co-localization of Rab27b-EBFP and Aβ in Rab27b samples
Co-localization of Rab27b-EBFP and HiLyte Fluor 647-labeled Aβ42 and Aβ40 in N2A cells
pre- and post-treatment with ionomycin. White outlines represent the plasma membranes
of N2A cells. Scale bars represent 5 µm.
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Rab27b-EBFP and AB-40 Co-Localization

Figure 12 – Mean co-localization of Rab27b-EBFP and Aβ in Rab27b samples
(A) Rab27b-EBFP Q78L and HiLyte Fluor 647-labeled Aβ42 co-localization significantly
decreased post-treatment (N=5, n=28) with ionomycin in comparison to pre-treatment
(N=7, n=36) (p<0.05). (B) Rab27b-EBFP N133I and HiLyte Fluor 647-labeled Aβ40 colocalization significantly decreased post-treatment (N=5, n=35) with ionomycin in
comparison to pre-treatment (N=5, n=40) (p<0.05). Rab27b-EBFP WT and HiLyte Fluor
647-labeled Aβ40 co-localization significantly decreased post-treatment (N=6, n=42) with
ionomycin in comparison to pre-treatment (N=7, n=28) (p<0.05).
There were no differences in co-localization of Rab27b-EBFP and Aβ42 or Aβ40 between
Rab27b samples, as determined by Brown-Forsythe and Welch ANOVA tests followed by
post hoc Dunnett’s T3 multiple comparisons tests. Dark bars indicate pre-treatment with
ionomycin, and light bars indicate post-treatment with ionomycin. All results are presented
as normalized mean ± SEM. Asterisks indicate statistically significant changes between
pre- and post-treatment samples, as determined by unpaired t-tests with Welch’s correction.
*p<0.05
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3.4 Rab27b Mutants Alter Lysosomal-Mediated Secretion of
Exogenous Aβ
To establish the effects of Rab27b mutants on secretion of Aβ, N2A cells that were
transfected with LAMP1-mChFP and Rab27b-EBFP WT, Q78L, T23N, or N133I and
loaded with exogenous Aβ were imaged under confocal microscopy before and after
treatment with ionomycin. Images acquired pre- and post-treatment with ionomycin were
used to calculate percent co-localization of LAMP1-mChFP and HiLyte Fluor 647-labeled
Aβ42 or Aβ40 using Imaris Software 7. A signal intensity threshold of the top 2% of the data
was used for LAMP1-mChFP, a signal intensity threshold range of the top 0.5% to 2% of
the data was used for Aβ, and a signal intensity threshold range of the top 2% to 5% was
used for Rab27b. The raw mean co-localization percentages of LAMP1-mChFP and Aβ in
Rab27b samples are listed in Table 3.
Table 3 – Raw mean co-localization of LAMP1-mChFP and Aβ
Aβ

Aβ42

Aβ40

Rab27b
T23N
N133I
WT
Q78L
T23N
N133I
WT
Q78L

Pre-treatment
Co-localization (%)
45.36 ± 2.15
47.09 ± 3.68
44.49 ± 1.87
37.41 ± 4.95
40.17 ± 4.99
35.00 ± 5.13
32.48 ± 3.42
37.99 ± 3.47

Post-treatment
Co-localization (%)
31.86 ± 3.56
34.01 ± 2.40
26.56 ± 7.90
14.92 ± 4.91
28.23 ± 6.09
25.30 ± 2.82
13.21 ± 4.59
22.28 ± 6.15
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3.4.1 Aβ42: Pre-Treatment Between-Group Comparison
To confirm that results observed were not due to differences in Aβ loading, pre-treatment
percent co-localization of HiLyte Fluor 647-labeled Aβ42 and LAMP1-mChFP was
compared between Rab27b and control samples. Raw pre-treatment data was subjected to
Brown-Forsythe and Welch ANOVA tests followed by post hoc Dunnett’s T3 multiple
comparisons tests. There were no significant differences in HiLyte Fluor 647-labeled Aβ42
and LAMP1-mChFP co-localization between Rab27b and control samples pre-treatment
with ionomycin (Figure 13). Therefore, there were no differences in Aβ42 loading between
samples.

Pre-treatment: LAMP1-mChFP & AB-42 Co-Localization

Figure 13 – Pre-treatment co-localization of LAMP1 and Aβ42 in Rab27b samples
There were no significant differences in LAMP1-mChFP and HiLyte Fluor 647-labeled
Aβ42 co-localization between Rab27b and control samples pre-treatment with ionomycin,
as determined by Brown-Forsythe and Welch ANOVA tests followed by post hoc
Dunnett’s T3 multiple comparisons tests. All results are presented as raw mean ± SEM.
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3.4.2 Aβ42: Within-Group Comparison
To determine whether there was a difference in pre- and post-treatment percent colocalization of LAMP1-mChFP and HiLyte Fluor 647-labeled Aβ42, normalized data was
subjected to unpaired t-tests with Welch’s correction. LAMP1-mChFP and HiLyte Fluor
647-labeled Aβ42 co-localization significantly decreased post-treatment (N=3, n=48) with
ionomycin in comparison to pre-treatment (N=3, n=141) (p<0.0001) in control samples
(Figure 5 and Figure 18). LAMP1-mChFP and HiLyte Fluor 647-labeled Aβ42 colocalization significantly decreased post-treatment (N=6, n=39) with ionomycin in
comparison to pre-treatment (N=6, n=39) (p<0.05) in Rab27b T23N samples. This was a
29.76% ± 9.17% decrease in co-localization (Figure 14 and Figure 18). LAMP1-mChFP
and HiLyte Fluor 647-labeled Aβ42 co-localization significantly decreased post-treatment
(N=5, n=28) with ionomycin in comparison to pre-treatment (N=7, n=36) (p<0.05) in
Rab27b N133I samples. This was a 27.79% ± 9.33% decrease in co-localization (Figure 15
and Figure 18). There were no significant differences in LAMP1-mChFP and HiLyte Fluor
647-labeled Aβ42 co-localization post-treatment (N=5, n=28) with ionomycin in
comparison to pre-treatment (N=7, n=32) in Rab27b WT samples (Figure 16 and Figure
18). LAMP1-mChFP and HiLyte Fluor 647-labeled Aβ42 co-localization significantly
decreased post-treatment (N=5, n=28) with ionomycin in comparison to pre-treatment
(N=7, n=36) (p<0.01) in Rab27b Q78L samples. This was a 60.12% ± 18.63% decrease in
co-localization (Figure 17 and Figure 18). Overall, Rab27b mutants and control underwent
significant lysosomal-mediated Aβ42 secretion.
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Figure 14 – Co-localization of LAMP1-mChFP and Aβ42 in T23N samples
LAMP1-mChFP and Aβ42 co-localization decreased post-treatment in comparison to pretreatment in Rab27b T23N samples. White outlines represent the plasma membranes of
N2A cells. Scale bars represent 5 µm.
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Figure 15 – Co-localization of LAMP1-mChFP and Aβ42 in N133I samples
LAMP1-mChFP and Aβ42 co-localization decreased post-treatment in comparison to pretreatment in Rab27b N133I samples. White outlines represent the plasma membranes of
N2A cells. Scale bars represent 5 µm.
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Figure 16 – Co-localization of LAMP1-mChFP and Aβ42 in WT samples
LAMP1-mChFP and Aβ42 co-localization did not decrease post-treatment in comparison to
pre-treatment in Rab27b WT samples. White outlines represent the plasma membranes of
N2A cells. Scale bars represent 5 µm.
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Figure 17 – Co-localization of LAMP1-mChFP and Aβ42 in Q78L samples
LAMP1-mChFP and Aβ42 co-localization decreased post-treatment in comparison to pretreatment in Rab27b Q78L samples. White outlines represent the plasma membranes of
N2A cells. Scale bars represent 5 µm.

53

LAMP1-mChFP and AB-42 Co-Localization

Figure 18 – Mean co-localization of LAMP1-mChFP and Aβ42 in Rab27b samples
LAMP1-mChFP and HiLyte Fluor 647-labeled Aβ42 co-localization significantly decreased
post-treatment (N=3, n=48) with ionomycin in comparison to pre-treatment (N=3, n=141)
(p<0.0001) in control samples. LAMP1-mChFP and HiLyte Fluor 647-labeled Aβ42 colocalization significantly decreased post-treatment (N=6, n=39) with ionomycin in
comparison to pre-treatment (N=6, n=39) (p<0.05) in Rab27b T23N samples. LAMP1mChFP and HiLyte Fluor 647-labeled Aβ42 co-localization significantly decreased posttreatment (N=5, n=28) with ionomycin in comparison to pre-treatment (N=7, n=36)
(p<0.05) in Rab27b N133I samples. LAMP1-mChFP and HiLyte Fluor 647-labeled Aβ42
co-localization significantly decreased post-treatment (N=5, n=28) with ionomycin in
comparison to pre-treatment (N=7, n=36) (p<0.01) in Rab27b Q78L samples. Dark bars
indicate pre-treatment with ionomycin, and light bars indicate post-treatment with
ionomycin. All results are presented as normalized mean ± SEM. Asterisks indicate
statistically significant changes post-treatment with ionomycin in comparison to pretreatment, as determined by unpaired t-tests with Welch’s correction. *p<0.05, **p<0.01,
****p<0.0001
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3.4.3 Aβ42: Post-Treatment Between-Group Comparison
To determine whether there was a difference in lysosomal-mediated secretion of Aβ42
between Rab27b and control samples, post-treatment percent co-localization of LAMP1mChFP and HiLyte Fluor 647-labeled Aβ42 was compared. Normalized post-treatment data
was subjected to Brown-Forsythe and Welch ANOVA tests followed by post hoc Dunnett’s
T3 multiple comparisons tests. LAMP1-mChFP and HiLyte Fluor 647-labeled Aβ42 colocalization was significantly lower in control samples (N=3, n=48) post-treatment with
ionomycin in comparison to Rab27b T23N (N=6, n=39) (p<0.01) and N133I samples (N=5,
n=35) (p<0.001). This was a percent difference of 58.13% ± 8.24% and 60.11% ± 5.68%,
respectively. There were no significant differences in LAMP1-mChFP and Aβ42 colocalization amongst WT and Q78L samples post-treatment with ionomycin (Figure 19).
Therefore, Rab27b dominant-negative mutants significantly reduced lysosomal-mediated
Aβ42 secretion when compared to control.

Post-treatment: LAMP1-mChFP & AB-42 Co-Localization

Figure 19 – Post-treatment co-localization of LAMP1 and Aβ42 in Rab27b samples
LAMP1-mChFP and HiLyte Fluor 647-labeled Aβ42 co-localization was significantly
lower in control samples (N=3, n=48) post-treatment with ionomycin in comparison to
Rab27b T23N (N=6, n=39) (p<0.01) and N133I samples (N=5, n=35) (p<0.001). All results
are presented as normalized mean ± SEM. Asterisks indicate statistically significant
changes between post-treatment samples, as determined by Brown-Forsythe and Welch
ANOVA tests followed by post hoc Dunnett’s T3 multiple comparisons tests. **p<0.01,
***p<0.001
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3.4.4 Aβ40: Pre-Treatment Between-Group Comparison
To confirm that results observed were not due to differences in Aβ loading, pre-treatment
percent co-localization of HiLyte Fluor 647-labeled Aβ40 and LAMP1-mChFP was
compared between Rab27b and control samples. Raw pre-treatment data was subjected to
Brown-Forsythe and Welch ANOVA tests followed by post hoc Dunnett’s T3 multiple
comparisons tests. Similar to Aβ42, there were no significant differences in HiLyte Fluor
647-labeled Aβ40 and LAMP1-mChFP co-localization between Rab27b and control
samples pre-treatment with ionomycin (Figure 20). Therefore, there were no differences in
Aβ40 loading between samples.

Pre-treatment: LAMP1-mChFP & AB-40 Co-Localization

Figure 20 – Pre-treatment co-localization of LAMP1 and Aβ40 in Rab27b samples
There were no significant differences in LAMP1-mChFP and HiLyte Fluor 647-labeled
Aβ40 co-localization between Rab27b and control samples pre-treatment with ionomycin,
as determined by Brown-Forsythe and Welch ANOVA tests followed by post hoc
Dunnett’s T3 multiple comparisons tests. All results are presented as raw mean ± SEM.
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3.4.5 Aβ40: Within-Group Comparison
To determine whether there was a difference in pre- and post-treatment percent colocalization of LAMP1-mChFP and HiLyte Fluor 647-labeled Aβ40, normalized data was
subjected to unpaired t-tests with Welch’s correction. LAMP1-mChFP and HiLyte Fluor
647-labeled Aβ40 co-localization significantly decreased post-treatment (N=3, n=37) with
ionomycin in comparison to pre-treatment (N=5, n=106) (p<0.0001) in control samples
(Figure 6 and Figure 25). There were no significant differences in LAMP1-mChFP and
HiLyte Fluor 647-labeled Aβ40 co-localization post-treatment (N=7, n=44) with ionomycin
in comparison to pre-treatment (N=4, n=19) in Rab27b T23N samples (Figure 21 and
Figure 25). There were no significant differences in LAMP1-mChFP and HiLyte Fluor
647-labeled Aβ40 co-localization post-treatment (N=7, n=43) with ionomycin in
comparison to pre-treatment (N=5, n=18) in Rab27b N133I samples (Figure 22 and Figure
25). LAMP1-mChFP and HiLyte Fluor 647-labeled Aβ40 co-localization significantly
decreased post-treatment (N=6, n=42) with ionomycin in comparison to pre-treatment
(N=7, n=28) (p<0.01) in Rab27b WT samples. This was a 59.33% ± 17.62% decrease in
co-localization (Figure 23 and Figure 25). There were no significant differences in LAMP1mChFP and Aβ40 co-localization post-treatment (N=6, n=35) in comparison to pretreatment (N=6, n=24) in Rab27b Q78L samples (Figure 24 and Figure 25). Overall,
Rab27b WT and control underwent significant lysosomal-mediated Aβ40 secretion.
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Figure 21 – Co-localization of LAMP1-mChFP and Aβ40 in T23N samples
LAMP1-mChFP and Aβ40 co-localization did not decrease post-treatment in comparison to
pre-treatment in Rab27b T23N samples. White outlines represent the plasma membranes
of N2A cells. Scale bars represent 5 µm.
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Figure 22 – Co-localization of LAMP1-mChFP and Aβ40 in N133I samples
LAMP1-mChFP and Aβ40 co-localization did not decrease post-treatment in comparison to
pre-treatment in Rab27b N133I samples. White outlines represent the plasma membranes
of N2A cells. Scale bars represent 5 µm.
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Figure 23 – Co-localization of LAMP1-mChFP and Aβ40 in WT samples
LAMP1-mChFP and Aβ40 co-localization decreased post-treatment in comparison to pretreatment in Rab27b WT samples. White outlines represent the plasma membranes of N2A
cells. Scale bars represent 5 µm.
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Figure 24 – Co-localization of LAMP1-mChFP and Aβ40 in Q78L samples
LAMP1-mChFP and Aβ40 co-localization did not decrease post-treatment in comparison to
pre-treatment in Rab27b Q78L samples. White outlines represent the plasma membranes
of N2A cells. Scale bars represent 5 µm.
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LAMP1-mChFP and AB-40 Co-Localization

Figure 25 – Mean co-localization of LAMP1-mChFP and Aβ40 in Rab27b samples
LAMP1-mChFP and HiLyte Fluor 647-labeled Aβ40 co-localization significantly decreased
post-treatment (N=3, n=37) with ionomycin in comparison to pre-treatment (N=5, n=106)
(p<0.0001) in control samples. LAMP1-mChFP and HiLyte Fluor 647-labeled Aβ40 colocalization significantly decreased post-treatment (N=6, n=42) with ionomycin in
comparison to pre-treatment (N=7, n=28) (p<0.01) in Rab27b WT samples. Dark bars
indicate pre-treatment with ionomycin, and light bars indicate post-treatment with
ionomycin. All results are presented as normalized mean ± SEM. Asterisks indicate
statistically significant changes post-treatment with ionomycin in comparison to pretreatment, as determined by unpaired t-tests with Welch’s correction. **p<0.01,
****p<0.0001
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3.4.6 Aβ40: Post-Treatment Between-Group Comparison
To determine whether there was a difference in lysosomal-mediated secretion of Aβ40
between Rab27b and control samples, post-treatment percent co-localization of LAMP1mChFP and HiLyte Fluor 647-labeled Aβ40 was compared. Normalized post-treatment data
was subjected to Brown-Forsythe and Welch ANOVA tests followed by post hoc Dunnett’s
T3 multiple comparisons tests. LAMP1-mChFP and HiLyte Fluor 647-labeled Aβ40 colocalization was significantly lower in control samples (N=3, n=37) post-treatment with
ionomycin in comparison to Rab27b N133I samples (N=7, n=43) (p<0.01). This was a
percent difference of 47.87% ± 9.79% (Figure 26). Therefore, Rab27b N133I significantly
reduced lysosomal-mediated Aβ40 secretion when compared to control.

Post-treatment: LAMP1-mChFP and AB-40 Co-Localization

Figure 26 – Post-treatment co-localization of LAMP1 and Aβ40 in Rab27b samples
LAMP1-mChFP and HiLyte Fluor 647-labeled Aβ40 co-localization was significantly
lower in control samples (N=3, n=37) post-treatment with ionomycin in comparison to
Rab27b N133I samples (N=7, n=43) (p<0.01). All results are presented as normalized mean
± SEM. Asterisks indicate statistically significant changes between post-treatment samples,
as determined by Brown-Forsythe and Welch ANOVA tests followed by post hoc
Dunnett’s T3 multiple comparisons tests. **p<0.01
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3.5 Differences in Aβ Secretion in Rab27b Samples
To determine whether there was a difference between Aβ42 and Aβ40 secretion in Rab27b
samples, normalized pre- and post-treatment data were subjected to unpaired t-tests with
Welch’s correction, in addition to Brown-Forsythe and Welch ANOVA tests followed by
post hoc Dunnett’s T3 multiple comparisons tests. There were no significant differences
post-treatment with ionomycin in comparison to pre-treatment when comparing between
Aβ40 and Aβ42 groups, in Rab27b T23N, N133I, WT, and Q78L samples (Figure 27).
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Rab27b T23N: LAMP1-mChFP & AB Co-Localization
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Rab27b N133I: LAMP1-mChFP & AB Co-Localization
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Rab27b WT: LAMP1-mChFP & AB Co-Localization
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Rab27b Q78L: LAMP1-mChFP & AB Co-Localization

Figure 27 – Mean co-localization of LAMP1-mChFP and Aβ in Rab27b samples
(A) LAMP1-mChFP and HiLyte Fluor 647-labeled Aβ42 co-localization significantly
decreased post-treatment (N=6, n=39) with ionomycin in comparison to pre-treatment
(N=6, n=39) (p<0.05) in Rab27b T23N samples. (B) LAMP1-mChFP and HiLyte Fluor
647-labeled Aβ42 co-localization significantly decreased post-treatment (N=5, n=35) with
ionomycin in comparison to pre-treatment (N=5, n=40) (p<0.05) in Rab27b N133I samples.
(C) LAMP1-mChFP and HiLyte Fluor 647-labeled Aβ40 co-localization significantly
decreased post-treatment (N=6, n=42) with ionomycin in comparison to pre-treatment
(N=7, n=28) (p<0.01) in Rab27b WT samples. (D) LAMP1-mChFP and HiLyte Fluor 647labeled Aβ42 co-localization significantly decreased post-treatment (N=5, n=28) with
ionomycin in comparison to pre-treatment (N=7, n=36) (p<0.01) in Rab27b Q78L samples.
There were no significant differences in co-localization of LAMP1-mChFP and HiLyte
Fluor 647-labeled Aβ in Rab27b T23N, N133I, WT, and Q78L samples when comparing
between Aβ42 and Aβ40 groups. Dark bars indicate pre-treatment with ionomycin, and light
bars indicate post-treatment with ionomycin. All results are presented as normalized mean
± SEM. Asterisks indicate statistically significant changes between pre- and post-treatment
samples, as determined by unpaired t-tests with Welch’s correction. *p<0.05, **p<0.01
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Chapter 4

4

Discussion

This study was conducted to establish the means of Aβ secretion in the context of
Alzheimer’s disease (AD). In accordance with results observed in numerous studies [2]–
[4], [137], [142], [165], it was hypothesized that secretion of Aβ would be mediated by
lysosomes in a Rab27b-dependent manner (Figure 4). We aimed to: 1) demonstrate storage
of Aβ42 and Aβ40 within lysosomes, 2) demonstrate lysosomal-mediated secretion of Aβ42
and Aβ40, 3) establish the effects of Rab27b mutants on Rab27b distribution, and 4)
establish the effects of Rab27b mutants on secretion of Aβ42 and Aβ40. We predicted that:
1) loading of Neuro-2a (N2A) cells with exogenous Aβ40 and Aβ42 will result in storage of
exogenous Aβ42 and Aβ40 in lysosomes, 2) initiation of calcium-dependent exocytosis with
calcium ionophore ionomycin will result in secretion of lysosome-stored exogenous Aβ42
and Aβ40, 3) there will be an increase in co-localization of Rab27b and lysosomes posttreatment with ionomycin in comparison to pre-treatment in Rab27b wild-type (WT)
samples loaded with Aβ42 or Aβ40, 4) there will be no significant differences in colocalization of Rab27b and lysosomes post-treatment in comparison to pre-treatment in
Rab27b mutant (T23N, N133I, and Q78L) samples loaded with Aβ42 or Aβ40, 5) there will
be a decrease in co-localization of Rab27b and Aβ42 or Aβ40 post-treatment in comparison
to pre-treatment in Rab27b WT samples, 6) there will be no significant differences in colocalization of Rab27b and Aβ42 or Aβ40 post-treatment in comparison to pre-treatment in
Rab27b mutant samples, 7) Rab27b T23N and N133I samples will secrete significantly less
Aβ42 and Aβ40 in comparison to Rab27b WT, Q78L and control samples, when stimulated
with ionomycin, 8) Rab27b Q78L samples will secrete significantly more Aβ42 and Aβ40 in
comparison to Rab27b T23N, N133I, WT and control samples, and 9) there will be no
significant differences in secretion of Aβ42 in comparison to secretion of Aβ40, in control
and Rab27b samples.
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4.1 Aβ Secretion is Mediated by Lysosomes
In line with our predictions, LAMP1-mChFP co-localized with exogenous Aβ42 and Aβ40
pre-treatment with ionomycin in control samples.
Co-localization of LAMP1-mChFP and Aβ42 or Aβ40 was significantly reduced posttreatment with ionomycin in comparison to pre-treatment in control samples. Rather than
remaining stored within lysosomes, Aβ42 and Aβ40 were observed as extracellular
accumulations proximal to the plasma membranes of N2A cells. These results demonstrate
that exogenous Aβ42 and Aβ40 can be stored within and subsequently secreted by
lysosomes.
4.1.1 Intracellular and Extracellular Aβ Observations
Proteases are enzymes that catalyze the breakdown of proteins via hydrolysis. Many in vivo
and in vitro studies have observed that the breakdown of Aβ can be mediated by proteases
such as neprilysin (NEP), insulin degrading enzyme (IDE), and cathepsin D. Cathepsin D
in particular is a resident lysosomal aspartyl protease that has been shown to be elevated in
extracellular amyloid plaques in the brains of both transgenic AD mice and humans with
AD, suggesting that cathepsin D may play a role in AD prevention by catalyzing the
breakdown of Aβ [4], [166]. However, previous studies have shown that Aβ aggregation
can result in structural changes in Aβ that confer resistance to protease activity [142], [170].
Indeed, studies observing cathepsin D-mediated cleavage of Aβ utilized monomeric forms
of this protein in their experiments, rather than aggregated forms [171]. In accordance with
this finding, many studies have observed that an acidic pH promotes the aggregation of Aβ,
with exogenous Aβ observed to accumulate specifically within lysosomal lumens [3].
These results suggest that Aβ can aggregate within the lysosome prior to its extracellular
release and evade digestion by resident lysosomal acid hydrolases due to its aggregated
structure. In addition to intracellular aggregation, Aβ aggregates have been observed to
associate with lipid rafts on the extracellular surface of cells to induce further Aβ
aggregation and neurotoxicity [145].
Our observations provide evidence that support many of these previous findings. Although
exogenous Aβ was added to cells in monomeric form, we observed accumulations of Aβ
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specifically within the lumens of lysosomes, prior to treatment with ionomycin. In being
able to evade degradation by lysosomal proteases, this observation suggests that the
accumulation of Aβ either occurred within the lysosome at a very fast rate, or that it was
first initiated within late endosomes/MVBs and Aβ accumulations were then trafficked to
lysosomes. It is interesting to note that the lysosomal accumulation of Aβ peptides and the
ability of Aβ to evade degradation within lysosomes is comparable to lysosomal storage
diseases (LSDs). In LSDs, material that has been trafficked to lysosomes cannot be
degraded (for example, due to a mutation in the material’s corresponding acid hydrolase)
and thus accumulates within the compartment, resulting in a variety of symptoms [40].
After treatment with ionomycin, we observed Aβ accumulations to be associated with the
extracellular surface of the plasma membranes of fixed N2A cells. It is possible that these
Aβ accumulations occurred within lipid rafts of plasma membranes [145], [146], due to the
hydrophobic properties of Aβ [141], [142].

4.2 Subcellular Distribution of Rab27b
Distribution of Rab27b WT relative to LAMP1-mChFP slightly varied from our initial
predictions. Although LAMP1-mChFP and Rab27b-EBFP were predicted to increase in
co-localization post-treatment with ionomycin in comparison to pre-treatment in WT
samples loaded with Aβ42 or Aβ40, we observed no significant differences in co-localization
post-treatment in comparison to pre-treatment. The initial prediction was made in line with
previous findings indicating that active Rab27b is recruited to the membranes of lysosomes
through interactions involving Rab-GDIs and GDFs during calcium-dependent exocytosis
[86], [87]. We therefore reasoned that distribution of Rab27b WT should be diffuse pretreatment due to sequestration of Rab27b in the cytosol, and should be localized to the
membranes of lysosomes upon initiation of exocytosis with ionomycin. This pattern of
distribution has previously been observed with Rab27a expression [169]. Our unexpected
result might be attributed to the rate that Rab27b WT underwent a catalytic cycle (GTPbound to GDP-bound) and the length of the ionomycin treatment. It is possible that within
Rab27b WT samples, active Rab27b was recruited to the membranes of lysosomes to
enable vesicle docking after addition of ionomycin. However, over the span of the twominute treatment, a large portion of active Rab27b might have undergone catalytic cycles
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such that the majority would have become inactive and sequestered within the cytosol prior
to fixation with PFA. If this were the case, Rab27b distribution in Rab27b WT samples
would have been diffuse within the cytosol and would have resulted in a low amount of
LAMP1-mChFP and Rab27b-EBFP co-localization, both pre- and post-treatment. This
pattern of distribution and co-localization was indeed observed.
Distributions of Rab27b T23N, N133I, and Q78L relative to LAMP1-mChFP were
consistent with initial predictions. LAMP1-mChFP and Rab27b-EBFP co-localization was
expected to not change post-treatment relative to pre-treatment in Rab27b T23N, N133I,
and Q78L mutants loaded with Aβ42 or Aβ40. This was predicted because ionomycin
treatment should not alter the effects of Rab27b proteins that are always active (Q78L) or
always inactive (T23N and N133I). As such, co-localization of LAMP1-mChFP and
Rab27b-EBFP in Rab27b Q78L samples should have remained high (relative to all other
Rab27b samples) both pre- and post-treatment, while co-localization in Rab27b T23N and
N133I samples should have remained low. Subcellular distribution of Rab27b T23N and
N133I in particular should have been diffuse throughout the cytosol both pre- and posttreatment. Accordingly, there were no significant differences in post-treatment colocalization of LAMP1-mChFP and Rab27b-EBFP in comparison to pre-treatment in
Rab27b mutants. It is important to note that pre- and post-treatment co-localization of
LAMP1-mChFP and Rab27b-EBFP in all Rab27b mutants was low, although Rab27b
T23N and N133I did appear to distribute more diffusely in the cytosol, in comparison to
Rab27b Q78L.
Distribution of Rab27b WT relative to Aβ varied from our initial predictions. Colocalization of Rab27b-EBFP and Aβ42 or Aβ40 was predicted to decrease post-treatment in
comparison to pre-treatment in Rab27b WT samples. This was expected because Rab27b
WT samples should have undergone normal lysosomal-mediated exocytosis upon
treatment with ionomycin, such that there would have been a decrease in amount of Aβ
within lysosomal lumens post-treatment in comparison to pre-treatment. This result was
observed in Rab27b WT samples that were loaded with Aβ40. Rab27b WT samples that
were loaded with Aβ42, however, did not display significant differences in amount of
Rab27b-EBFP and Aβ42 co-localization post-treatment in comparison to pre-treatment.
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Distributions of Rab27b T23N, N133I, and Q78L relative to Aβ likewise varied from our
initial predictions. It was predicted that co-localization of Rab27b-EBFP and Aβ42 or Aβ40
would not be altered post-treatment in comparison to pre-treatment in Rab27b mutant
samples. As described for distribution of Rab27b relative to LAMP1-mChFP, addition of
ionomycin should not alter the effects of Rab27b proteins that are always active (Q78L) or
always inactive (T23N and N133I). Co-localization of Rab27b-EBFP and Aβ42 or Aβ40
should therefore always remain low in Rab27b Q78L samples, as Rab27b Q78L samples
should always be undergoing lysosomal-mediated exocytosis. Similarly, co-localization of
Rab27b-EBFP and Aβ42 or Aβ40 should always remain low in Rab27b T23N and N133I
samples, as dominant-negative Rab27b cannot facilitate lysosomal-mediated exocytosis.
Results supported predictions for all Rab27b mutant samples, with the exception of Rab27b
Q78L samples loaded with Aβ42 and Rab27b N133I samples loaded with Aβ40. In these
samples, co-localization of Rab27b-EBFP and Aβ significantly decreased post-treatment
in comparison to pre-treatment.

4.3 Rab27b Mutants Alter Lysosomal-Mediated Secretion of
Exogenous Aβ
When comparing within Rab27b samples, lysosomal-mediated secretion of Aβ varied from
initial predictions. Within-group comparisons of LAMP1-mChFP and Aβ42 co-localization
demonstrated significant decreases in Rab27b T23N, N133I, and Q78L post-treatment
samples when compared to their respective pre-treatment samples. We did not observe a
similar significant decrease in Rab27b T23N, N133I, and Q78L samples when comparing
LAMP1-mChFP and Aβ40 co-localization. Instead, we observed significant decreases in
LAMP1-mChFP and Aβ40 co-localization in Rab27b WT post-treatment samples when
compared to Rab27b WT pre-treatment samples. Aβ40 findings were consistent with our
initial predictions and are consistent with our current knowledge of Rab GTPases. As
mentioned for subcellular distribution above, Rab27b WT is expected to act as a normal
Rab GTPase. Specifically, active Rab27b WT should interact with Munc13-4 to dock the
lysosome at the plasma membrane and enable calcium-dependent exocytosis of Aβ to occur
upon treatment with ionomycin. This would result in decreased post-treatment colocalization of LAMP1-mChFP and Aβ in comparison to pre-treatment, as was observed.
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Akin to subcellular distribution, Rab27b T23N, N133I, and Q78L post-treatment colocalization of LAMP1-mChFP and Aβ should not be altered in comparison to pretreatment, as these Rab GTPases are consistently inactive (T23N and N133I) or active
(Q78L) regardless of treatment with ionomycin.
It is important to note that despite our predictions, a general decrease in post-treatment colocalization of LAMP1-mChFP and Aβ in comparison to pre-treatment was observed in all
Rab27b samples. One possible explanation for this observation in Rab27b T23N and N133I
samples is functional compensation by other Rab GTPases upon inactivity of Rab27b. As
described in Section 1.3.2, Rab27 isoforms have been modeled to act separately,
cooperatively, redundantly, or sequentially (contingent on cell type and secretory pathway).
The “redundant activity” model of Rab27 suggests that Rab27a and Rab27b act in parallel
to elicit the same response(s), due to targeting of the same effector protein(s) [9]. If one of
these isoforms was not able to function, the other isoform would compensate accordingly.
In line with this theory, both Rab27a and Rab27b have been shown to interact with effector
protein Munc13-4 [7], [92]. It is likely that functional compensation can occur in the
pancreas and in pituitary tissues, where Rab27a and Rab27b are both expressed [169],
[172]. However, only isoform Rab27b has been localized to the brain [172]. Previous
studies have shown that small GTPase Rab3a both localizes to the brain and functions in a
similar manner to Rab27b, suggesting that Rab3a may be able to compensate for inactivity
of Rab27b (T23N and N133I) during exocytosis [93].
When comparing between Rab27b samples, lysosomal-mediated secretion of Aβ in Rab27b
Q78L samples differed from initial predictions. Although we expected to observe
significantly greater secretion of Aβ in Rab27b Q78L samples in comparison to Rab27b
T23N, N133I, WT and control samples, we observed no significant differences in secretion
of Aβ in Rab27b Q78L samples in relation to all other samples. Nevertheless, there was a
trend toward significance that was clearly observed in Rab27b Q78L samples loaded with
Aβ42, demonstrated by a decrease in post-treatment co-localization of LAMP1-mChFP and
Aβ42 in these samples when compared to Rab27b N133I, T23N, WT and control samples.
One explanation for this finding entails permanent binding of Rab27b Q78L to lysosomal
membranes. Specifically, as Rab27b Q78L is always bound to GTP, Rab27b Q78L would
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likely remain permanently attached to the lysosomal membrane to which it was initially
recruited. After stimulation of calcium-dependent exocytosis, Rab27b Q78L would remain
permanently attached to the plasma membrane. This is due to the inability of Rab-GDI to
sequester active Rab GTPases in the cytosol. In other words, Rab27b Q78L would not be
able to be recycled [87]. If this were the case, the number of lysosomes that undergo
exocytosis in Rab27b Q78L samples and the amount of intraluminal Aβ released to the
extracellular space would be limited by the amount of Rab27b Q78L that is initially
expressed in the cell.
Conversely, lysosomal-mediated secretion of Aβ in Rab27b dominant-negative samples
coincided with initial predictions. We observed significantly less secretion of Aβ42 in
Rab27b T23N and N133I samples relative to control samples. This was demonstrated by a
significant increase in post-treatment co-localization of LAMP1-mChFP and Aβ42 in
Rab27b T23N and N133I samples when compared to control samples. Similarly, we
observed significantly less secretion of Aβ40 in Rab27b N133I samples relative to control
samples, demonstrated by a significant increase in post-treatment co-localization of
LAMP1-mChFP and Aβ40 in Rab27b N133I samples when compared to control samples.
These results suggest that lysosomal-mediated secretion of Aβ is dependent on Rab27b.
Despite its increased hydrophobicity and associated propensity to aggregate [141], [142],
there is no evidence to suggest that Aβ40 would secrete in a different manner relative to
variant Aβ42. Accordingly, there were no significant differences in pre- or post-treatment
co-localization of LAMP1-mChFP and Aβ in Rab27b T23N, N133I, WT, and Q78L
samples when comparing between Aβ42 and Aβ40 groups. Therefore, there were no
significant differences in lysosomal-mediated secretion of Aβ in Rab27b T23N, N133I,
WT, and Q78L samples when comparing between Aβ42 and Aβ40 groups.
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4.4 Relation to In Vivo Calcium-Dependent Exocytosis
The Neuro-2a (N2A) cells used in this study were neuroblast cells derived from Mus
musculus neuroblastoma (ATCC). Neuroblasts are post-mitotic primitive nerve cells that
are committed to developing into neurons upon differentiation, or maturation [173]. Both
neurons and their primitive counterparts are excitable cells; therefore, they are capable of
propagating electrical signals (action potentials) upon depolarization that surpasses a
threshold value [174]. Neurons and neuroblasts possess an intracellular negative charge at
rest. Depolarization can be defined as an increase in intracellular positive charge, such that
the extracellular and intracellular charge difference is reduced. In neurons and neuroblasts,
initial depolarization is dependent on an influx of sodium ions (Na+) through voltage-gated
sodium channels [175]. As mentioned above, sufficient depolarization can result in an
action potential that is propagated through the neuron or neuroblast [174], which in turn
enables the opening of voltage-gated calcium channels. This opening allows the influx of
Ca2+ from the extracellular space to the cytosol [175], in addition to calcium-induced
calcium release (CICR) from ryanodine receptors (RyR) and inositol 1,4,5-trisphosphate
receptors (IP3Rs) of the endoplasmic reticulum (ER) [70]–[72]. An increase in intracellular
Ca2+ is necessary for Synaptotagmin-mediated fusion of vesicles to occur during calciumdependent exocytosis [66], [73], as described in Section 1.2.1. Due to increases in
intracellular Ca2+ concentration, treatment of cells with ionomycin results in a process that
mimics calcium-dependent exocytosis in vivo while by-passing the requirement of an action
potential. This is due to the mechanism of action of ionomycin. As a calcium ionophore,
ionomycin can directly increase intracellular Ca2+ to induce transient vesicle fusion [76].
Because ionomycin is able to directly increase the intracellular Ca2+ concentration, an
associated problem with excessive application of this ionophore is calcium overload [176].
Calcium overload has been shown in many studies to elicit cell death through the activation
of pro-apoptotic factors, such as cytochrome c [177], [178]. To avoid calcium overload and
subsequent cell death in this study, the minimum concentration of ionomycin required to
elicit calcium-dependent exocytosis in N2A cells was added to each sample (1 µM). This
amount was determined by titrating the concentration of ionomycin that was used to treat
samples, prior to the start of experiments.
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4.5 Conclusion
4.5.1 Significance
AD is a progressive neurodegenerative disease that decreases quality of life tremendously.
Afflicted individuals experience symptoms of dementia and personality changes that
negatively affect both themselves and their loved ones [102]. As no curative treatments are
currently available for AD, therapeutic approaches rely on medication that purely alleviate
symptoms [113]. Presently, there are over 750 000 Canadians living with AD [103]. With
increasing age being a primary risk factor for progression of AD [104], the aging population
of baby boomers are predicted to yield more than 130 million new cases of AD worldwide
by the year 2050 [179]. Conducting relevant research can both enhance our understanding
of how this disease progresses and facilitate the development of treatments that target
underlying disease mechanisms, overall reducing the occurrence of future AD cases.
The basis of this study was the amyloid cascade hypothesis of AD, which postulates that
the production of Aβ prompts AD development [121]. This hypothesis is supported by
numerous studies showing that the overexpression of Amyloid Precursor Protein (APP) can
result in the development of AD. As the gene encoding APP is found on chromosome 21,
this was an especially important finding for individuals with Down syndrome (Trisomy 21)
that possess an extra copy of chromosome 21 and are therefore likely to develop AD at
some point in their lives [161], [162]. The discovery of autosomal dominant mutations in
APP, PSEN1, and PSEN2 genes that are directly linked to early-onset forms of AD
(Familial AD) strongly support the amyloid cascade hypothesis as well [158].
In accordance with the amyloid cascade hypothesis, we aimed to elucidate the manner in
which Aβ was being secreted from cells. As previous research suggested that lysosomes
and small GTPase Rab27b may be involved in secretion of Aβ [2], [3], [7], we conducted
experiments that allowed us to manipulate Rab27b activity while directly and indirectly
observing lysosomal-mediated secretion of Aβ. We observed that lysosomes can undergo
calcium-dependent exocytosis and release Aβ to the extracellular space. Moreover, we
observed that this process was dependent on small GTPase Rab27b. These results reveal a
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pharmaceutical target (Rab27b) that may alter the amount of Aβ that is being secreted from
cells when its activity is modified.
4.5.2 Limitations
The results of this study demonstrate that lysosomal-mediated exocytosis of Aβ may in part
rely on the activity of Rab27b. However, no significant differences were observed in posttreatment co-localization of LAMP1-mChFP and Aβ42 or Aβ40 when comparing Rab27b
WT samples to Rab27b mutant samples. It is important to note that the pattern of
endogenous Rab27b expression and turnover is presently unknown and as such, total
amount of endogenous Rab27b protein present in a cell at any one time is unknown. As
endogenous Rab27b expression was not altered in this study, control samples expressed
less Rab27b protein than Rab27b WT samples. Moreover, Rab27b WT protein expression
was mediated by a constitutive cytomegalovirus promoter. This resulted in a pattern of
Rab27b expression that did not mimic that of endogenous Rab27b expression in Rab27b
WT samples, and instead gave rise to an overexpression system. When comparing control
samples to Rab27b WT samples, there were no significant differences in LAMP1-mChFP
and Aβ42 or Aβ40 co-localization post-treatment with ionomycin. However, there was a
trend toward significance; specifically, amount of LAMP1-mChFP and Aβ42 or Aβ40 colocalization post-treatment with ionomycin was higher in Rab27b WT samples than control
samples. These observations may be indicative of an issue in Rab27b overexpression
systems. It is possible that even minor overexpression of Rab27b can modify the activity
of effector protein Munc13-4. For example, overexpression of Rab27b (WT and Q78L)
may result in over-recruitment of Munc13-4. This over-recruitment could lead to unstable
ternary bundle formation due to sequestration of bundle proteins by disproportionate
Rab27b-Munc13-4 complexes, which would ultimately reduce the amount of exocytosis
that the cell can undergo.
When focusing on pre-treatment raw data, approximately 40% of exogenous Aβ colocalized with LAMP1-mChFP (on average, across samples). As only a minimal amount
of Aβ was observed in the extracellular space by eye, this suggests that at least 50% of Aβ
was both internalized and stored in subcellular locations other than the lysosome. It is
possible that overnight incubation with exogenous Aβ did not allow all the incubated Aβ
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to enter lysosomes. Consistent with APP processing and the endocytic pathway [18], [180],
the remainder of Aβ could potentially be found in early endosomes and/or late
endosomes/multivesicular bodies (MVBs). Likewise, not all Aβ that was loaded into cells
was released upon initiation of calcium-dependent exocytosis. This might be due to an
insufficient concentration of ionomycin that was used to treat the samples. This is unlikely,
as various concentrations of ionomycin were tested on N2A cells prior to initiation of
experiments, thus allowing us to elucidate the minimum concentration of ionomycin
required to elicit an exocytotic response in N2A cells (as described in Section 4.4).
It is also possible that calcium-dependent exocytosis of Aβ did not solely occur via
lysosomes. Indeed, secretory vesicles and late endosomes/MVBs are also capable of
undergoing calcium-dependent exocytosis [21]. In addition, APP processing and
production of Aβ has been shown in previous studies to ensue within the trans-Golgi
network (TGN) [181]. In accordance with this observation, it is possible that Aβ can be
packaged into secretory vesicles that subsequently follow the constitutive pathway of
exocytosis. Furthermore, rather than functioning as an intermediate compartment for
transfer of APP and/or Aβ from the early endosome to the lysosome, it is very possible that
late endosomes/MVBs may mediate the secretion of Aβ directly [182], [183]. As late
endosomes/MVBs contain numerous ILVs, fusion of a late endosome/MVB with the
plasma membrane during exocytosis would result in the release of ILVs to the extracellular
space. These extracellular vesicles are termed exosomes [183]. Despite its ability to recruit
only a few (known) types of effector proteins, Rab27b has been shown to recruit effector
Slac2-b during secretion of exosomes in HeLa cells [184].
The foremost limitation of this study, however, was the use of exogenous Aβ as opposed
to observation of endogenous Aβ. It is possible that the exogenous Aβ that was utilized
does not traffic or secrete in a similar manner as endogenous Aβ in AD. Although difficult
to say whether this is unlikely, the Aβ that was used in this study was derived from humans
and carefully prepared, handled, and stored to maintain its monomeric form prior to
treatment of cells.
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4.5.3 Future Directions
Future experiments related to this study may consider repeating the experiments described
herein with a focus on other small GTPases or SNAREs that have also been shown to be
important for lysosomal-mediated secretion. These proteins can include ternary bundle
SNARE proteins VAMP-2, Syntaxin-11, and SNAP-23 [67], [91]. For example, cells could
be transfected with LAMP1-mChFP and VAMP-2 WT or mutant constructs, loaded with
exogenous Aβ, and imaged under confocal microscopy before and after treatment with
ionomycin. This would allow one to observe whether secretion of Aβ is dependent on
VAMP-2. Future experiments might also consider repeating this study with a focus on other
subcellular compartments that could be mediating secretion of Aβ. These compartments
can include late endosomes/MVBs and associated exosomes [182]. Experiments can also
be repeated in neurons derived from the brain of an AD mouse model, or human neurons
derived from epilepsy patients (via temporal lobe resections). Cells of these types may
secrete Aβ in a manner more similar to neurons in the brains of individuals with AD, in
comparison to the N2A cells that were used in this study. Use of AD mouse models may
also provide with the additional advantage of being able to observe trafficking and secretion
of endogenous Aβ.
It might also be useful for future experiments to silence endogenous Rab27b expression
using small interfering ribonucleic acid (siRNA), for example. Such a study would allow
for direct comparison of Aβ secretion between Rab27b control and knockdown samples.
Use of Rab27b WT samples (cells transfected with a Rab27b WT construct) in these
experiments would further elucidate whether overexpression of Rab27b can indeed reduce
lysosomal-mediated secretion, potentially through sequestration of proteins as described in
Section 4.5.2. It would also be interesting to compare the effects of gene silencing and
alteration of gene expression on upstream versus downstream calcium-dependent
exocytosis factors. For example, we might observe different results in secretion of Aβ if
we were to shift our focus from Rab27b to exocyst subunit EXOC6.
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